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ABSTRACT 
 
Adenosine is an endogenous nucleoside that has been recognised to be a molecule with 
autocrine/paracrine functions, acting as a signal molecule to preserve host defence and 
tissue integrity during inflammation and trauma in addition to its important role as 
homeostatic regulator. The physiological activities of adenosine involve its interactions with 
four types of receptors, designed as A1, A2A, A2B and A3. Adenosine mediates its anti-
inflammatory activity primarily through the A2A receptor (A2AAR). The ecto-
5’nucleotidase/CD73 degrades adenosine 5’-monophosphate (AMP) to adenosine and 
represents a key enzyme for adenosine accumulation at the site of injury. Aim of this 
research work was to explore different aspects of adenosine signalling pathway in 
inflammation.  
Several findings implicate the adenosine signalling pathway as an innate mechanism to 
attenuate excessive tissue damage and identify CD73 as critical control points for 
endogenous adenosine generation. It has been shown that CD73 plays an important role in 
regulating vascular permeability and leukocyte trafficking in inflammatory disease; and a 
crucial role in the regulation of immune/inflammatory cell function. A better understanding 
of the role of CD73 enzyme in the development of inflammatory processes can help to 
identify new therapeutic strategies aimed at strengthening the endogenous anti-
inflammatory mechanisms. For this reason, we sought to investigate the role of CD73, the 
key enzyme in “switching on” adenosine signalling, in the development of  inflammation 
through its pharmacological blockade by using the selective inhibitor, adenosine 5'-(α,β-
methylene) diphosphate (APCP; 400 μg/site), in an in vivo model of acute inflammation 
represented by carrageenan-induced pleurisy in rats. We found that local inhibition of CD73 
significantly increased cell accumulation, exudate formation and pro-inflammatory cytokine 
 xiii 
 
content into the pleural cavity in the acute phase of inflammation with no differences in the 
sub-acute phase. The in vivo treatment with APCP induced cells recruited into the pleural 
cavity to change in a phenotype with increased ability to migrate in vitro either in presence 
or in absence of a chemotactic stimulus. In parallel, these cells showed a reduced CD73 
expression and activity compared to cells collected from control group. In addition, APCP, 
in vitro, strongly increased the ability of cells from control groups to migrate in presence of 
a chemotactic stimulus. Local inhibition of CD73 increased also the infiltration of the lung 
with polymorphonuclear leukocytes (PMNs) and the degree of lung injury 4 hours following 
carrageenan injection.  
The interest to explore the role of adenosine signalling pathway in the control of 
inflammation has been growing further following evidence that adenosine signalling is also 
involved in the mechanism of action of some well-known anti-inflammatory drugs. With 
regard to this, we focused our interest on the possible involvement of adenosine signalling 
in the anti-inflammatory mechanism of nimesulide, in vivo (rat paw oedema) and in vitro 
(J774A.1cell line); indeed, there is evidence that nimesulide anti-inflammatory effect is the 
consequence of regulation of the production and actions of a wide range of inflammatory 
mediators, independently from the sole cyclooxygenase-2 (COX-2) enzyme  inhibition. To 
date, the molecular mechanisms at the basis of nimesulide peculiar pharmacological effects 
are still unclear. In vivo, in the model of carrageenan-induced rat paw oedema, we found 
that the anti-inflammatory effect of nimesulide (5 mg/kg i.p.) was inhibited by pre-treatment 
with the adenosine A2A receptor antagonist, ZM 241385 (3 mg/kg i.p.), and by local 
administration of the CD73 inhibitor, APCP (400 μg/paw). Furthermore, we observed 
increased activity of 5'-nucleotidase/CD73 in plasma and paws of nimesulide-treated rats,  4 
h following oedema induction that represented the inflammatory peaking point. In vitro, the 
inhibitory effect of nimesulide on nitrite and prostaglandin (PG)E2 (PGE2) production by 
 xiv 
 
lipopolysaccharide (LPS)-activated J774 macrophage cell line was again reverted by ZM 
241385 and APCP. Furthermore, nimesulide increased CD73 activity in J774 macrophages 
while it did not inhibit nitrite accumulation by LPS-activated small interfering RNA 
(SiRNA) CD73 silenced J774 macrophages. Our data demonstrate that the anti-
inflammatory effect of nimesulide is, in part, mediated by CD73-derived adenosine acting 
on A2A receptors.  
There is evidence that A2AAR activation beside anti-inflammatory effects promotes wound 
healing and extracellular matrix production; given that extracellular matrix and fibroblasts 
take an active part in the modulation of inflammation beside wound healing, we investigated 
whether and how extracellular matrix was involved in the anti-inflammatory effect of A2A 
receptor. Specifically, we evaluated changes in tissue fibroblast growth factor-2 (FGF-2), an 
important growth factor for fibroblasts that has been shown to facilitate not only tissue 
regeneration but also to dampen inflammation, following systemic administration of the A2A 
agonist, CGS 21680, in a rat model of acute inflammation (paw oedema). We observed that 
CGS 21680 prevented oedema development and inflammation, confirming an anti-
inflammatory effect of A2AR. The effect of CGS 21680 was specific, through A2A adenosine 
receptor stimulation, as revealed by co-administration with ZM 241385 that reverted CGS 
21680 inhibitory effect. On the basis of histological analysis showing an increased matrix 
deposition following rat treatment with CGS 21680, we evaluated whether the beneficial 
effect of A2A agonist, CGS 21680, was paralleled by changes in FGF-2 expression. 
Interestingly, we found that the expression of FGF-2 in rat paws, evaluated at each hour 
following carrageenan injection, was increased following rat treatment with CGS 21680. 
Immunofluorescence analysis confirmed data obtained by western blotting and also showed 
spots of co-localization between A2AR and FGF-2.  
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In conclusion, in this research work we demonstrate that CD73 regulates cell migration in 
the acute phase of inflammation and that the anti-inflammatory effects mediated by A2AR 
activation are paralleled by changes in extracellular matrix morphology. These findings 
suggest the important role of CD73/adenosine/A2A signalling in the control of the acute 
phase of inflammation, characterised by PMNs infiltration, but also in the control of a late 
phase, characterised by re-arrangement of extracellular matrix. In addition, we also 
demonstrate that CD73/adenosine/A2A axis is involved in the mode of action of nimesulide. 
Our study may open a path to re-evaluate the mechanism of action of nimesulide and to 
identify new therapeutic opportunities in COX-2 inhibitors which display a more potent 
activity on adenosine signalling. Furthermore, these results may give the cue to project an 
innovative anti-inflammatory strategy based on the manipulation of endogenous anti-
inflammatory pathways. 
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1. INTRODUCTION 
 
1.1 ADENOSINE AND INFLAMMATORY RESPONSE 
1.1.1 Inflammatory response 
Inflammation is a physiological response to disrupted tissue homeostasis caused by 
endogenous and exogenous stimuli that involves a complex biological cascade of molecular 
and cellular signals. The end-point of inflammation is to rapidly destroy or isolate the 
underlying source of the disturbance, to remove damaged tissue and, then, to restore tissue 
homeostasis (Medzhitov, 2008). Classically, inflammation is characterized by rubor 
(redness), tumor (swelling), calor (heat), dolor (pain), and functio laesa (loss of function), 
symptoms caused by increased blood flow to the affected area, leakage of fluid into tissues 
and the accumulation of activated leukocytes. 
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Figure 1. A primer of the inflammatory cascade. Adapted from Noah TA, Zachary M, Weil, Randy JN. 
(2012) Annu Rev Ecol Evol Syst. 43:385–406. Inflammation is induced by pathogens, tissue injury, and 
foreign particles (a). The first step of the inflammatory cascade is the recognition of infection or damage (b) 
that is generally accomplished by the detection of pathogen-associated molecular patterns (PAMPs), or by 
endogenous molecules such as alarmins and damage-associated molecular patterns (DAMPs). Many damage 
signals are recognized by germ-line encoded receptors, such as transmembrane Toll-like receptors (TLRs) and 
intracellular nucleotide-binding domain and leucine-rich-repeat containing receptors (NOD-like receptors or 
NLRs). Once recognition of ligands occurs, TLRs activate of common signalling pathways that culminate in 
the activation of NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells; c). Transcription and 
translation of target genes lead to the third stage of the inflammatory cascade, which is the inducible 
expression of pro-inflammatory cytokines, such as interleukin-1-beta (IL- 1β), Interleukin-6 (IL-6), tumor 
necrosis factor-alpha (TNF-α), and others (d). NLRs signal the inflammasome, which activates caspase-1 to 
convert cytokines into active forms (IL-1β and Interleukin-18 (IL-18), which then elicit inflammation after 
being released from the cell (d). Therefore, a variety of pro-inflammatory cytokines and chemokines are 
produced and released to promote effector functions of inflammation. Chemokines (attractants) and various 
costimulatory molecules, facilitate the recruitment of effector cells (e), such as monocytes and neutrophils, to 
the site of disturbance; blood-borne neutrophils and monocytes migrate to the site of disturbance by 
chemotaxis selectively pass through endothelial cells to reach target sites (extravasation). Mast cells and 
tissue-resident macrophages promote this migration by releasing histamine, leukotrienes, and prostaglandins, 
which have rapid effects upon the vasculature, including vasodilation and increased vascular permeability. 
Neutrophils create a cytotoxic environment by releasing noxious chemicals from cytoplasmic granules (a 
process called degranulation). Rapid release of these chemicals requires consumption of both glucose and 
oxygen, known as the respiratory burst. Toxic chemicals released include highly reactive oxygen and nitrogen 
species (ROS and RNS, respectively) and various proteinases. These substances are destructive to both 
pathogens and hosts. The effector functions of inflammation are further regulated by the adaptive immune 
system (f). When stimulated by cells presenting antigen, naïve Th cells (Th0; never exposed to antigen) can 
differentiate into several different types of effector and regulatory cells: Th1 cells (pro-inflammatory), Th2 
cells (anti-inflammatory), regulatory T-cells (Tregs), and Th17 cells (pro-inflammatory).  
Inflammation resolves when the injurious agent is eliminated and mediators produced are 
demolished or missing. Although inflammatory response is usually beneficial, it can also be 
potentially harmful to the host. Thus, regulatory endogenous anti-inflammatory mechanisms 
that limit damage from an excessive immune response have evolved. It has become clear 
that the resolution of inflammation is an active phenomenon that is orchestrated by 
endogenous “pro-resolving” mediators in a highly coordinated way, acting as a "metabolic 
switch" necessary to preserve the organism defense and tissue integrity (Gilroy et al., 2004). 
During the past years, a large number of cellular and molecular anti-inflammatory and pro-
resolution mediators have been identified including annexin-1, lipoxins, resolvins, 
protectins, maresins, adenosine (Buckley et al., 2013). When the regulatory mechanisms of 
the inflammatory response are defective or the ability to clear damaged tissue and foreign 
substances is impaired, a prolonged and damaging inflammatory response occurs. (Nathan, 
2002; Serhan and Savill, 2005; Lawrence and Gilroy, 2007). Inappropriate or prolonged 
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inflammation is the main cause of many disorders including asthma (Barnes, 1999), cancer 
(Coussens and Werb, 2002), atherosclerosis (Libby, 2002), autoimmune disease, 
Alzheimer's and Parkinson's diseases (Amor et al., 2014); therefore, it is important to 
understand the physiological mechanisms that sense excessive damage and contribute to 
terminate inflammation.  
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cellular and molecular components of the inflammatory response and the requirements for 
resolution. Adapted from Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, 
Rossi AG, Wallace JL. (2007) FASEB J. 21:325-32. At the beginning of the inflammatory response, pro-
inflammatory mediators are mainly released, which initiate and augment the acute phase of the response (A). 
However, this is counterbalanced by endogenous anti-inflammatory signals such as corticosterone, which 
 
  
 
A 
 
 
 B 
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serve to temper the severity and limit the duration of the early onset phase. As inflammation progresses, 
certain “stop signals” at appropriate “checkpoints” prevent further leukocyte traffic into tissue. These stop 
signals include the lipoxins, resolvins, prostaglandins (PGs) of the D series and adenosine and pave the way 
for monocyte migration and their differentiation to phagocytosing macrophages, which remove dead cells and 
then exit the site of inflammation. Stromal cells such as fibroblasts also contribute to the resolution of 
inflammation by the withdrawal of survival signals and the normalization of chemokine gradients, thereby 
allowing infiltrating leukocytes to undergo apoptosis or leave the tissue through the draining lymphatics. This 
sequential set of responses leads to complete resolution and, importantly, the restoration of the inflamed tissue 
to its prior physiological functioning. This is the ideal sequence of events in physiological inflammation, 
which contrast to the situation in pathological inflammation (B) where some of the factors that initiate the 
resolution program lead to the inappropriate accumulation of leukocytes in the wrong place at the wrong time. 
Current anti-inflammatory therapy is largely based on the blocking of key pro-inflammatory 
mediator pathways that are elicited on the initiation of an acute inflammatory response, an 
innovative strategy to manage inflammation could be the pharmacological manipulation of 
endogenous anti-inflammatory mechanisms.  
 
1.1.2 Adenosine  
Adenosine is an endogenous ubiquitous  purine nucleoside, composed of adenine linked to a 
ribose  via a β-N9-glycosidic bond (Figure 3).    
 
Figure 3.  Chemical structure of adenosine 
Adenosine was first recognized to reduce heart rate, blood pressure and to induce coronary 
vasodilatation by Drury and Szent-Györgyu  in 1929. Since then, it has become clear that in 
addition to functioning as central factor in the biochemistry of energy production, adenosine 
regulates numerous cellular functions. There is evidence that adenosine acts as a key 
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regulatory molecule, mostly protective but in certain scenarios injurious, in the 
pathophysiology of inflammatory diseases (Haskó and Pacher, 2008). For this reason, 
adenosine has been variously called as “signal of life,” “retaliatory metabolite,” and “body’s 
natural defense” (Engler, 1991; Cohen and Downey, 2008) as a consequence of its ability to 
mediate an auto-regulatory loop, whose function is to protect organs from injury following 
the initiating stressful stimuli such as during inflammation (Newby, 1984; Haskó and 
Cronstein, 2004).  
1.1.3 Adenosine formation and metabolism 
Adenosine is constitutively present at low concentrations intracellularly as well as 
extracellularly and it is a product of complete dephosphorylation of adenine nucleotides. 
Adenosine intracellular production is mediated either by an intracellular 5′-nucleotidase, 
cytoplasmic 5’-nucleotidase (cN-I), that breaks down AMP to adenosine (Phillips and 
Newsholme, 1979; Zimmermann et al., 1998; Sala-Newby et al.,1999) or by hydrolysis of 
S-adenosyl-L-homocysteine (SAH) by the activity of the S-adenosyl-L-homocysteine 
hydrolase (SAHH) (Broch and Ueland, 1980). Within cells, adenosine is an intermediate for 
the synthesis of nucleic acids and adenosine 5’-triphosphate (ATP). Adenosine generated 
intracellularly is transported into the extracellular space mainly via specific bi-directional 
transporters through facilitated diffusion that efficiently evens out the intra- and 
extracellular levels of adenosine. In some tissues such as the kidney, there is a concentrative 
nucleoside transport protein capable of maintaining high adenosine concentrations against a 
concentration gradient. These transport proteins are termed “equilibrative nucleoside 
transporter” (ENT1 and ENT2), for the equilibrative transport,  and “concentrative 
nucleoside transporter” (CNT1 and CNT2), for the concentrative types (Jennings et al., 
1998). 
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On the other hand, after intracellular reuptake, adenosine can be phosphorylated to AMP by 
adenosine kinase (AK) (Spychala et al., 1996) or deaminated to inosine by adenosine 
deaminase (ADA) (Fox and Kelley, 1978). ADA, but not AK, is also present in the 
extracellular space (Lloyd and Fredholm, 1995). Inosine produced can be expelled from the 
cell or be degraded to hypoxanthine, xanthine and ultimately to uric acid (Kovács et al., 
2011).  These pathways ensure the maintenance of intracellular adenosine concentrations 
through a strict enzymatic control. 
 
Figure 4. Adenosine formation and metabolism in the cell.  From Borowiec, Lechward, Tkacz-Stachowska, 
Składanowski. (2006) Acta Biochim Pol. 53:269-78. For abbreviations, see abbreviation list. 
Under basal conditions, adenosine extracellular levels are in nanomolar range, from 30 to 
200 nM  (Ballarín et al., 1991)  and the maintenance of these concentrations depends on a 
balance between the release/removal of the nucleoside by membrane transporters/enzymes 
and its formation from ATP due to the activity of ecto-nucleotidases. 
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In the extracellular space, adenosine is produced via enzymatic hydrolysis of extracellular 
ATP in a two-step enzymatic process regulated by coupled cell ectoenzymes. In this 
cascade, the ecto-nucleoside triphosphate diphosphohydrolase 1 (E-NTPD1, also known as 
CD39) dephosphorylates ATP to adenosine 5’-diphosphate (ADP) and AMP whereupon 
ecto-5' nucleotidase (e-5’NT, also known as CD73) hydrolyses AMP to adenosine 
(Zimmermann, 2000). Minor producers of extracellular adenosine include alkaline 
phosphatases and members of the nucleotide pyrophosphatase and phosphodiesterase 
family, which hydrolyse pyrophosphate bonds and phosphodiester bonds in nucleotides 
(Yegutkin, 2014).  
The half-life of adenosine in the extracellular space is about of 10 s. Under physiological 
conditions, most of the extracellular adenosine appears to re-enter cells through 
equilibrative transporters. A small fraction can be irreversibly converted into inosine and its 
derivatives (hypoxanthine, xanthine, uric acid) by ADA and xanthine oxidase. Extracellular 
adenosine can also be metabolized by ecto-kinases to regenerate AMP, ADP, and ATP 
(Yegutkin, 2014).  
Extracellular levels of adenosine can rise from low nanomolar to micromolar concentrations 
in response to increased metabolic demand, injury or stress, such as ischemia and 
inflammation, mainly by the breakdown of ATP released either by lysis or non-lytic 
mechanisms from multiple cell types (Fredholm, 2007).  The termination of extracellular 
adenosine signalling occurs by uptake or degradation of this nucleoside, achieved by 
nucleoside transporters and ecto-adenosine deaminase, respectively. Under pathological 
conditions, there is a parallel marked induction of enzymes that are responsible for ATP-
dependent adenosine signalling as well as of adenosine receptors and, in contrast,  the 
suppression of enzymes involved in adenosine metabolism, such as AK (Chen et al., 2013). 
The reason for the adenosine extracellular increase is related to the activation of an auto 
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regulatory loop, whose  function  is to protect organs from injury following the initiating 
stressful stimuli (Bours et al., 2006). 
 
Figure 5. Adenosine synthesis and metabolic pathways outside of a cell. Adapted from Antonioli L, 
Blandizzi C, Csóka B, Pacher P, Haskó G. (2015) Nat Rev Endocrinol. 11:228-41. For abbreviations, see 
abbreviation list.         
1.1.4 Adenosine receptors and signal transduction mechanism 
Adenosine signalling is evoked through activation of four distinct and widely expressed 
receptors: A1, A2A, A2B and A3. All four subtypes, known as purinoceptors P1, are members 
of the superfamily of G-protein-coupled receptors (GPCRs) which transfer signals by 
activating heterotrimeric G proteins (Ralevic and Burnstock, 1998). Adenosine receptors 
display the typical topology of GPCRs, characterized by a common central core domain 
consisting of seven transmembrane helices numbered from 1 to 7 that are composed of 20-
27 amino acids and that are largely α-helical, with an extracellular amino-terminus and an 
intracellular carboxy-terminus (Ralevic and Burnstock, 1998).  
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First evidence for the existence of adenosine receptors was in 1965 when DeGubareff and 
Sleator observed that adenosine action on heart could be antagonized by caffeine; 
subsequently, in 1970, Sattin and Rall showed that adenosine regulates cell function via 
occupancy of specific receptors on the cell surface. To date, adenosine receptors have been 
cloned, and the signal transduction mechanisms have been described. Classically, the first 
effector molecule of adenosine receptors is the enzyme adenyl cyclase (AC) which is either 
stimulated or inhibited, increasing or decreasing cyclic adenosine monophosphate cAMP 
levels according to the receptor subtype triggered (van Calker et al., 1979). 
Adenosine receptors have been implicated in several biological functions, both 
physiological and pathological. These receptors have distinct localization, signal 
transduction pathways and different regulation upon exposure to agonists (Ralevic and 
Burnstock, 1998). Moreover, the expression levels of all the adenosine receptors are 
transcriptionally regulated and can change rapidly and dramatically in response to various 
stimuli (Murphree et al., 2005). A1 and A2A adenosine receptors possess high affinity for 
adenosine (Km< 30 nM) whereas A3 and, in particular, the A2B adenosine receptors are low 
affinity receptors (Km 1–20 μM). Thus, A2B and A3 adenosine receptors are likely only 
activated under high metabolic and stressful cellular conditions (Fredholm et al., 2001).  
1.1.4.1 A1 adenosine receptor 
A1 adenosine receptor (A1AR) is coupled to G proteins belonging to the family of the Gi/Gq. 
Activation of A1AR inhibits AC activity through activation of pertussis toxin-sensitive Gi 
proteins, it decreases PKA activity and phosphorylation of the cyclic AMP response element 
binding (CREB) protein (Van Calker et al., 1979). In cardiac muscle and neurons, A1AR 
can activate pertussis toxin-sensitive K+ channels, as well as KATP channels, and inhibit Q-, 
P- and N-type Ca
2+
 channels. Furthermore, activation of A1AR leads to increased 
intracellular Ca
2+
 levels due to the stimulation of phospholipase C (PLC), which in turn 
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promotes the cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3) (Stiles, 1992). Moreover, the enhancement of 
intracellular calcium can activate certain enzymes, such as protein kinase C (PKC), 
phospholipase D (PLD), phospholipase A2 (PLA2). Activation of A1AR can also increase 
mitogen-activated protein kinase (MAPK pathway in cells of the Chinese hamster ovary and 
COS-7 fibroblast-like cells by βγ subunit of Gi/o protein. A1AR is widely distributed and is 
expressed in the central nervous system (neocortex, cerebellum, hippocampus and the dorsal 
horn of the spinal cord); adipose tissue, skeletal muscle, liver, kidney, salivary glands, 
esophagus, colon, eyes, heart muscle (sinoatrial and atrioventricular nodes, ventricles); 
lungs, pancreas and inflammatory cells such as neutrophils (Polosa, 2002).  
1.1.4.2 A2A adenosine receptor 
A2 adenosine receptors are subdivided into the A2A and A2B receptors, based on high and 
low affinity for adenosine, respectively. High levels of the A2A receptor are found in brain 
striatum, immune cells of the spleen, thymus, leukocytes and in blood platelets;  
intermediate levels are found in the heart, lung and blood vessels.  A2A adenosine receptor 
(A2AAR) couples to Gs protein in peripheral tissues or Golf protein in the brain (Kull et al., 
2000). Increased cAMP level stimulates cAMP-dependent kinase (protein kinase A, PKA) 
which, in turn, activates several pathways through calcium channels, potassium channels, 
CREB, MAPK and PLC activation. Activation of A2AAR can also promote activation of 
PKC in a cAMP-dependent and independent mechanisms (Sheth et al., 2014). There is 
evidence that the A2AAR can occur as receptor homodimer as well as heterodimers with 
other receptors such as dopamine D2 receptor (Fredholm et al., 2007). Moreover, recent 
studies have shown that there are several proteins interacting with the cytoplasmic tail of the 
activated A2AAR resulting in G-protein-independent signalling pathways (Fredholm et al., 
2007). 
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1.1.4.3 A2B adenosine receptor  
A2B adenosine receptor (A2BAR) is widely expressed in the brain, gastrointestinal tract, 
bladder, lung and on endothelial cells, muscle cells, mast cells, fibroblasts (Polosa, 2002). 
Activation of A2BAR can stimulate  AC and  PLC through activation of Gs and Gq proteins, 
respectively (Feoktistov  and Biaggioni, 1995). The A2BAR has also been described to be 
involved in the extracellular signal-regulated kinase (ERK) ERK1, ERK2 (Schulte and 
Fredholm, 2003) and p38 MAPK in mast cells. 
1.1.4.4 A3 adenosine receptor 
A3 adenosine receptor (A3AR) couples to classical second-messenger pathways such as 
inhibition of AC, stimulation of PLC and D and calcium mobilization (Zhou et al., 1992;  
Abbracchio et al., 1995). A3AR can regulate the activity of PLC via a pertussis toxin-
sensitive G protein in rat basophilic leukemia cells or by direct coupling to Gq protein. It has 
been widely identified in several tissues and cell type, including kidney, testis, lung, mast 
cells, eosinophils, neutrophils, heart and in brain cortex (Polosa, 2002). In the heart, A3AR 
mediates cardioprotective effects through the activation of KATP channels that are coupled to 
RhoA–phospholipase D signalling, mediating the protection of cardiac myocytes from 
ischemia. Like other adenosine receptors, A3 receptors are coupled to MAPK and lead to 
stimulation of ERK1/2.  
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Figure 6. Principal signalling pathways activated by adenosine receptors. From Padovan M,  Vincenzi F, 
Govoni M, Bortoluzzi A,  Borea PA; Varani K. (2013) Int J Clin Rheumatol. 8:13-25. For abbreviations, see 
abbreviation list.  
1.1.5. Overall effect of adenosine and its receptors on inflammation 
Adenosine has been recognised as an endogenous signalling molecule that is able to signal 
inflammation as well as modulate the inflammatory response (Haskó and Cronstein, 2013). 
Adenosine is one of the many biomolecules that accumulate in the inflammatory milieu 
conferring pleiotropic effects which can be beneficial or harmful (Driver et al., 1993). 
Adenosine effects are the outcome of receptor activation and may be pro-inflammatory or 
anti-inflammatory depending 1) on the tissue or cells where receptor are expressed, 2) on 
the affinity between adenosine and a specific receptor and 3) on the extent of tissue receptor 
expression under pathological conditions (Bours et al., 2006). Generally, at the early stage 
of the inflammatory process, high level of extracellular adenosine directs toward an immune 
response more specific. At the late stage of inflammation, adenosine resolves the 
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inflammation by downregulating immune cells. Extracellular adenosine regulates the 
function of the innate and adaptive immune systems through targeting virtually every cell 
type that is involved in orchestrating an immune/inflammatory response (Haskó and Pacher, 
2008).  
1.1.5.1 Adenosine and neutrophils 
Neutrophils are the most abundant circulating leukocytes, and are among the first cells to 
respond to injury; they represent the cellular hallmark of an acute inflammation. Neutrophils 
release adenosine but also respond to it via expression of all four adenosine receptor 
subtypes. The response of neutrophils to adenosine is highly dependent on the inflammatory 
microenvironment and, in part, regulated by the extent of expression of adenosine receptors 
on neutrophils and the affinity. Neutrophils are recruited to inflamed sites by a combination 
of chemokines and adhesive interactions  with the vascular endothelium. Adenosine acts on 
both neutrophils and endothelial cells to control neutrophil adhesion and transmigration. At 
early stages of inflammation, nanomolar concentrations of adenosine enhance neutrophil 
adhesion to the vascular endothelium by stimulation of A1 receptors on both neutrophils 
(Cronstein et al., 1992; Felsch et al., 1995) and endothelial cells (Zahler et al., 1994). Once 
the inflammatory reaction is in progress, adenosine micromolar concentrations inhibit the 
shedding of L-selectin and integrins (mainly CD11b/CD18) on neutrophils (Thiel et al., 
1996), the release of the neutrophil chemoattractant Interleukin-8 (IL-8) from endothelial 
cells and reduce expression of adhesion molecules endothelial-selectin (E-selectin) and 
vascular cell adhesion molecule 1 (VCAM-1) on the endothelial cell surface (Bouma et al., 
1996). These adenosine inhibitory effects are mediated trough A2A and A2B receptors. Also 
the A3AR has been implicated in the regulation of neutrophil adhesion since it reduces 
platelet activating factor (PAF)-stimulated neutrophil adherence to coronary endothelium 
(Jordan et al., 1999). Adenosine  acting via A2 receptors, inhibits pro-inflammatory 
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mediator release from activated neutrophils such as TNF-α and leukotriene B4 (LTB4) while 
promotes the release of anti-inflammatory mediators such as PGE2  (Pouliot et al., 2002; 
Cadieux et al., 2005). Similar to regulation of neutrophil chemotaxis, low concentrations of 
adenosine promote phagocytosis via A1 receptor binding, while elevated concentrations of 
adenosine inhibit phagocytosis via activation of A2A receptors (Salmon and Cronstein, 
1990). Adenosine appears to inhibit neutrophil granule release by binding  A2A  and A3 
receptors (Anderson et al., 2000) and to inhibit the neutrophil oxidative burst by activating 
A2A and A2B receptors (van der Hoeven et al., 2011; Sun et al., 2007). In contrast, 
A1 receptor activation enhances superoxide generation during FcRγ-mediated stimulation of 
human neutrophils. Cell death is essential to both homeostatic turnover of neutrophils in the 
resting state and during tissue inflammation. It has been demonstrated that adenosine 
analogues delay apoptosis of resting human neutrophils in culture (Walker et al., 1997a). 
1.1.5.2 Adenosine and mononuclear phagocyte system  
The mononuclear phagocyte system (MPS) is a family of cells comprising bone marrow 
progenitors, circulating monocytes, resident macrophages and dendritic cells (DCs) that 
have in common the property of phagocytosis. These cells synthesize and release into the 
environment cytokines and other proteins that play a central role in the development of 
acute and chronic inflammation and wound healing (van Furth and Cohn, 1968). A variable 
expression of adenosine receptors has been observed on monocytes (Thiele et al., 2004) and 
macrophages (Nemeth et al., 2005) which is based, at least in part, on their maturation 
phase. A1, A2 and A3 adenosine receptors are barely expressed on quiescent monocytes but 
their density  increases during the differentiation of monocytes into macrophages (Thiele et 
al., 2004). Adenosine receptor activation can influence macrophage function depending on 
the receptor subtypes expressed and the environment in which macrophages are exposed to 
extracellular adenosine. Endogenous adenosine is capable of preventing monocyte 
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maturation as demonstrated by the fact that ADA activity is increased during early 
monocyte differentiation and that ADA inhibition during this period delayed the maturation 
process (Fischer et al., 1976). High concentrations of exogenous adenosine seem to prevent 
monocyte development into macrophages and to arrest monocyte development at a stage 
with high accessory function, a phenotype that is similar to dendritic cells (Najar et al., 
1990). Adenosine influences monocyte maturation also by promoting the formation of 
multinucleated giant cells via A1 receptor stimulation, whereas A2 receptor activation 
prevents the generation of giant cells (Merrill et al., 1997). Adenosine suppresses 
macrophage colony-stimulating factor (MCF)-induced proliferation of mouse bone marrow 
macrophages through A2B receptors (Xaus et al., 1999). Regarding adenosine effect on 
monocyte/macrophage phagocytosis, it has been shown that the stimulatory effect of 
A1 adenosine receptors in undifferentiated monocytes is overcome by an A2 adenosine 
receptor-mediated suppression of phagocytosis in mature macrophages (Salmon et al., 
1993).  
The activation of A2A, A2B and A3 adenosine receptors suppresses the production of several 
pro-inflammatory cytokines, such as TNF-α, IL-6, Interleukin-12 (IL-12), macrophage 
inflammatory protein 1 alfa (MIP-1α)  by monocytes and macrophages thus promoting a 
polarization of monocyte and macrophage response toward an anti-inflammatory phenotype 
(Csóka et al., 2012,  Haskó et al., 1996; Haskó et al., 1998). In contrast, adenosine increases 
the production of the anti-inflammatory cytokine such as Interleukin-10 (IL-10) (Németh et 
al., 2005; Csóka et al., 2007). Adenosine has also shown to be a broad inhibitor of NO 
production by M1 macrophages (Haskó et al., 1996). Adenosine can affect monocyte 
adhesion during inflammation modulating the adhesion molecule expression on endothelium 
and also regulating the interactions between monocytes and the vascular endothelium 
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(Bours et al, 2006). Moreover, adenosine affects both RNS and ROS production by 
monocytes/macrophages (Si et al.,1997).  
Adenosine has also shown to modulate the functions of DCs, that are specialized antigen-
presenting cells characterized by their ability to migrate into target sites, to process antigens, 
and to activate naïve T cells. All four adenosine receptors are present on both immature 
myeloid and mature DCs (Panther et al., 2001). The modulation of DCs functions by 
adenosine depends on the expression of adenosine receptors, which is related to the 
maturation status of these cells. Immature human dendritic cells express mainly A1 and A3 
adenosine receptors which, once activated, stimulate immature dendritic cell recruitment to 
sites of inflammation via an increase in intracellular calcium. In contrast, dendritic cell 
maturation is associated with the upregulation of A2A adenosine receptor-mediated 
signalling responses, culminating in a decrease in pro-inflammatory cytokine release such as 
IL-6, IL-12, TNF-α (Panther et al.,2003; Schnurr et al., 2004). Adenosine also inhibits the 
expression of C-C chemokine receptor type 5 (CCR5), macrophage inflammatory protein 3 
beta MIP-3 β/chemokine (C-C motif) ligand 19 (CCL19), and multidrug resistance protein 1 
(MDR-1), molecules involved in dendritic cells migration, and slows the in vivo and in vitro 
migration of mature dendritic cells (Hofer et al., 2003). It has been demonstrated the 
involvement of A3 adenosine receptors in addition to A2A adenosine receptors in the 
inhibitory effect of adenosine on TNF release in DCs (Dickenson et al., 2003). It has been 
shown that adenosine enhances IL-10 secretion by mature DCs reducing their capacity to 
promote Th1 cell differentiation (Panther et al., 2003).  In the presence of toll-like receptor 
signalling, A2BAR activation inhibits DC-mediated T cell activation, indeed, its stimulation 
reduces lipopolysaccharide-induced surface expression of major histocompatibility complex 
class II (MHCII) molecules and cluster of differentiation 86 (CD86) which results in 
decreased Interleukin-2 (IL-2) expression by T cells. However, in the absence of toll-like 
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receptor signalling, the activation of the A2BAR can be pro-inflammatory causing the 
increases of pro-inflammatory IL-6, which together with transforming growth factor- β 
(TGF-β) can deviate naïve CD4+T cells to a Th17 phenotype that favors chronic 
inflammation.  
1.1.5.3 Adenosine and lymphocytes 
Chronic inflammation is often accompanied by recruitment of cell types participating in an 
immunological response, the lymphocytes. Adenosine has also been implicated in the 
regulation of lymphocyte function. It is well recognized that adenosine is an important 
endogenous immunosuppressing regulator; it has been demonstrated that the lack of the 
enzyme ADA is responsible for severe immunodeficient disease (Hirschhorn, 1995). 
Adenosine can regulate lymphocyte function indirectly by the activation of adenosine 
receptors on macrophages, dendritic cells, neutrophils, mast cells, in this way, by altering 
the production of several cytokines, such as TGF-β and IL-10 it produces an 
immunosuppressive environment. Adenosine can also regulate lymphocyte function directly 
by binding and activating adenosine receptors on lymphocytes (Bours et al., 2006). 
A2A, A2B and A3 adenosine receptors are expressed on human and mouse T lymphocytes and 
their activation appears to represent a potent endogenous immunosuppressive pathway that 
regulates the excessive immune response against potent external insults. Adenosine receptor 
subtype expression by T lymphocytes can be modulated by T cell receptor signalling, 
indeed activated human T lymphocytes exhibit elevated A2AAR, as well as A2BAR and 
A3AR (Mirabet et al., 1999; Gessi et al., 2004). A2A receptor is the major adenosine receptor 
influencing the function of lymphocytes (Huang et al., 1997). CD4
+
 rather than CD8
+
 T 
cells express A2A adenosine receptors. Adenosine potently inhibits a wide range of T 
lymphocyte responses to antigenic stimulation, including cellular proliferation (Ohta  et al., 
2009), synthesis of IL-2 by CD4
+
 T cells (Naganuma et al., 2006) and also by both 
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polarized TC1, TC2 CD8
+ 
cytotoxic cells (Erdmann et al.,  2005) and  synthesis of pro-
inflammatory cytokines such as TNF-α and interferon gamma (IFN-γ), by both naïve CD4+ 
T cells (Lappas et al., 2005; Naganuma et al., 2006) and polarized Th1 and Th2 cells 
(Csóka et al., 2008). In addition, both A2A and A2B adenosine receptors have been found on 
antigen-presenting cells (APCs) and strongly influence T cell activation. Moreover, 
adenosine by signalling primarily through A2A and A3 adenosine receptors on the surface of 
T cells provokes up-regulation of CD25 (IL-2 receptor α chain) (Huang et al., 1997; Butler 
et al., 2003), expression of cytotoxic effector molecules such as perforin and Fas ligand 
(Koshiba et al., 1997; Hoskin et al., 2002), and granule exocytosis by cytotoxic T 
lymphocyte (CTL) (Koshiba et al., 1997). A2AAR stimulation also upregulates the 
expression of negative costimulatory molecules such as cytotoxic T-lymphocyte antigen 4 
(CTLA-4) and down regulates expression of the positive costimulatory molecule CD40 
ligand (CD-40L) (Sevigny et al., 2007). Adenosine signalling has generally inhibitory 
effects on lymphocyte migration into the inflamed tissues; indeed, the extravasation of 
lymphocytes through blood vessels is influenced by A2A receptors-mediated suppression of 
intercellular adhesion molecule 1 expression on lymphocytes and diminished production of 
IFN-γ and IFN-γ-inducible chemokines that are chemotactic to activated lymphocytes 
(Henttinen et al., 2003). Adenosine also decreases the barrier function of vascular 
endothelium by activating A2BARs. Exposure to adenosine during T cell activation or in 
naïve T cells through A2AAR signalling promotes long-term T-cell anergy and the 
development of a regulatory phenotype (Treg) characterized by high expression of CD25, 
CTLA-4, and Forkhead box protein 3 (FoxP3) (Zarek et al., 2008). Next, Tregs not only 
utilize adenosine as one of their immunosuppressive mechanisms but also receive positive 
regulation from adenosine to enhance their number and immunosuppressive activity (Ohta 
et al., 2012). Thus, adenosine can not only directly and instantly inhibit the immune 
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response through its receptor on the effector cells, but also can recruit other 
immunoregulatory mechanisms, including Tregs.  
There is evidence that adenosine can regulate the differentiation and function of Th17 cells. 
It has been shown that A2A receptor activation limits the production of Th17 cells through 
suppression of IL-2 production (Zarek et al., 2008). In contrast, Wilson and co-workers 
(2011) have demonstrated that  adenosine represents a biological mediator that can enhance 
the development of Th17 cells acting at A2BRs. 
Natural killer (NK) cells express A1, A2A and A3 adenosine receptors. Adenosine acting at 
the A2A receptor of NK cells limits their capacity to produce pro-inflammatory cytokines 
such as TNF and IFN-γ while increases their production of Interleukin-4 (IL-4) and TGF 
(Lappas et al., 2006). A2AR activation also strongly inhibits the production of IFN-γ by 
invariant natural killer (iNKT) cells (Lappas et al., 2006; Nowak et al., 2010). Unlike 
conventional T cells, iNKT cells can be rapidly activated early during the inflammatory 
responses and produce copious amounts of cytokines shortly after T-cell receptor (TCR) 
engagement. Adenosine also inhibits both perforin and FasL cytotoxic molecules. In 
contrast, NK cell cytolytic function is enhanced through A1 and A3 receptor activation 
(Priebe et al., 1990; Harish et al., 2003; Raskovalova et al., 2005). 
B lymphocytes express all of four adenosine receptors (Sakowicz-Burkiewicz et al., 2012). 
It is likely that adenosine exerts its effect on B lymphocytes primarily through A2A 
receptors. It has been demonstrated that adenosine suppresses the proliferation and the 
antibody production of B cells (Seegmiller et al., 1977) and that adenosine affects B cells 
functions by inhibiting the activation of NF-kB in response to B cell antigen receptor (BCR) 
triggering (Minguet et al., 2005). Moreover, adenosine protects human B cells from B cell 
receptor-induced apoptosis mostly via A2A and A2B receptors and by downregulating 
caspase-3 activation (Sakata et al., 2000). 
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1.1.5.4 Adenosine and mast cells 
Mast cells  are bone marrow-derived inflammatory cells known for their involvement in 
allergic and inflammatory diseases; these cells can release mediators that have both 
immediate and chronic effects on airway constriction and inflammation. Adenosine 
receptors are expressed on mast cells with a different pattern depending on the species 
(human, murine, rat, etc.). Studies using pharmacological reagents and antisense DNA 
suggest that the A1 receptor is responsible for the mast cell-independent component of 
adenosine-induced bronchoconstriction (Ali et al., 1994). Adenosine can modulate mast cell 
degranulation but which receptor is involved is uncertain. For example, in vitro studies 
employing a human mast cell line and a dog mastocytoma line have shown a role for the 
A2B receptor in adenosine-induced mast cell activation (Feoktistov and Biaggioni, 1995; 
Auchampach et al., 1997) whereas in vitro and in vivo studies in rodent mast cells indicate 
that A3 adenosine receptor plays a primary role in mediating adenosine responses (Fozard et 
al., 1996; Reeves et al., 1997). However, these differences could be attributed to the 
selectivity of the adenosine analogs used, to different signalling pathways among mast cells 
from various tissues (or that have been generated in vitro using different methods), and to 
differences among species. It is possible that at low concentrations of adenosine, that are 
likely insufficient to activate the A2B and A3 adenosine receptors, only the high affinity A2A 
receptors signal prevails, downregulating mast-cell degranulation. It has been shown that 
basal levels of adenosine produced in the lung are insufficient to activate the A2B and A3 
adenosine receptors; conversely, in asthamatics, levels of adenosine into inflamed airway 
increase dramatically, and are sufficient to activate the A3AR and A2BAR (Driver et al., 
1993; Feoktistov et al., 1998). The infiltration of airway smooth muscle cells with mast cells 
in the asthmatic lung (Bradding and Brightling, 2007) coupled with this elevation in 
adenosine levels and subsequent activation of these cells via the A3 and/or A2B receptor may 
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play an important role in the pathogenesis of asthma as well as of other diseases in which 
coordinate increases in adenosine and mast cells is observed (Feoktistov et al., 1998; Tilley 
et al., 2003). 
 
Figure 7. Some representative actions mediated by adenosine in human immune cells. From  Antonioli L, 
Csóka B, Fornai M, Colucci R, Kókai E, Blandizzi C, Haskó G. (2014) Drug Discov Today. 19:1051-68. 
1.1.6 Adenosine receptors and inflammation  
It has been well documented that adenosine receptors play an important role in the 
regulation of inflammation, they may exert anti- or/and pro-inflammatory effects.  
1.1.6.1 A1AR  
The role of A1 receptor in inflammatory response is controversial. Several studies with 
selective agonists and antagonists have demonstrated pro-inflammatory effects of A1 
receptors in different inflammatory models. For example, in acute pancreatitis induced with 
cerulein or taurocholate in rats, the selective A1 receptors agonist CCPA produced an 
increase in leukocyte infiltration and interstitial edema in pancreatic tissue attenuated by 
FK-838, a selective A1 receptor antagonist (Satoh et al., 2000). In addition, treatment with 
DPCPX, an A1 receptor antagonist, has prevented endothelial damage, neutrophil migration 
 22 
 
and alveolar injury in a model of ischemia reperfusion in the lungs (Neely and Keith, 1995). 
On the other hand, studies using selective A1 receptor agonist or antagonists and knockout 
animals have shown that activation of the A1 receptor can promote anti-inflammatory 
effects. For instance, in a mouse model of renal ischemia reperfusion injury, it has been 
shown a protective effects of the A1 receptor, by using  A1 receptor agonist CCPA, and 
antagonist, DPCPX (Lee et al., 2004a), further confirmed in studies performed with A1 
receptor deficient mice (Lee et al., 2004b). Moreover, the absence of the A1 receptor has 
demonstrated to promote pro-inflammatory effects in the lungs, enhancing leukocyte 
migration and levels of cytokines, including IL-4 and IL-13 (Sun et al., 2005).  
In summary, the A1 receptor can activate intracellular signalling pathways that result in 
tissue injury or protection, through pro-inflammatory or anti-inflammatory effects, 
respectively, because the activated pathways depend on the species/tissue/organ and the 
stage/progression of injury, on the predominant inflammatory cell type as a function of 
species, on the intracellular signalling and desensitization mechanisms (da Rocha Lapa et 
al., 2014). 
1.1.6.2 A2AAR  
Unlike A1 receptors, there is a substantial consensus regarding the effects of A2A adenosine 
receptors on the inflammatory response. The central role of the A2AAR in counteracting 
inflammation has been demonstrated in numerous studies using A2AAR selective agonists to 
inhibit the inflammatory responses in a variety of cell types in vitro as well as  in vivo 
models of inflammation  and in studies using A2AAR deficient mice (Fredholm et al., 1996; 
Link et al., 2000; Ohta and Sitkovsky, 2001; Sitkovsky, 2003; Antonioli et al., 2006; Haskò 
and Pacher, 2008). The anti-inflammatory properties of A2AAR receptors are mediated, at 
least in part, by A2A adenosine receptors signalling on immune cells as described above. The 
anti-inflammatory effects of adenosine A2A receptor activation is due to the activation of 
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protein kinases which interfere with the IκB kinase complex that selectively inhibits the 
NFκB pathway, to the activation of CREB protein which mediates gene expression directly 
and indirectly by competing with the NFκB pathway and also through the activation of the 
exchange factor activated by cAMP which has a well-known immunosuppressive effect on 
immune cells (Huang et al., 1997;  Haskò and Cronstein,  2004). The tissue-protecting 
properties of A2A receptors have been well shown in different models of inflammatory 
damage and systemic inflammation such as ischemia reperfusion liver injury in mice (Day 
et al., 2004), inflammatory bowel disease (Odashima et al., 2005), in mouse models of 
endotoxemia and sepsis (Sullivan et al., 2004), in models of myocardial infarction, acute 
lung injury and spinal cord compression injury (Li et al., 2006; Yang et al., 2006; 
Reutershan et al., 2007). Furthermore, it has been demonstrated that A2AAR activation also 
protects from stress–induced gastric lesion in the rat that are dependent upon neutrophil 
infiltration (Odashima et al., 2006). On the other hand, in A2A receptor knockout mice has 
been shown the exacerbation of various types of inflammation, compared to wild-type mice, 
supporting the A2AAR dependent control of inflammation (Day et al., 2003; Nadeem et al., 
2007; Hussey et al., 2012). Moreover, experiments performed on knockout mouse models, 
have shown that A2AAR together with A3AR mediates the anti-inflammatory effect of 
methotrexate, which is used as a treatment of arthritis (Montesinos et al., 2003).  
It is well established that inflammatory tissue damage is accompanied by the accumulation 
of extracellular adenosine in inflamed sites due to its release from non-immune and immune 
cells. Because endogenous adenosine levels are elevated during an inflammatory process 
and endogenous adenosine can activate A2A receptors to attenuate inflammation and tissue 
damage, strategies that aim to raise adenosine production and its availability to activate A2A 
receptors present great anti-inflammatory potential.  
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1.1.6.3 A2BAR  
It has been found that A2BARs may mediate opposite responses in different types of 
inflammatory conditions in various tissues and/or at different stages of their progression 
(Feoktistov and Biaggioni,  2011). Several pharmacological studies have suggested that 
activation of A2BAR by adenosine has pro-inflammatory effects, mainly including the 
production of pro-inflammatory cytokines and chemokines (Feoktistov and Biaggioni, 1995; 
Zhong et al., 2004; Sun et al., 2006). However, Yang D. and co-workers (2006) have found 
that A2BAR knockout mice have increased inflammation at baseline and after LPS exposure, 
indicating that the A2BAR mediates anti-inflammatory responses. A2BAR knockout mice 
have also shown enhanced mast cell activation (Hua et al., 2007), confirming that the 
A2BAR plays an anti-inflammatory role at baseline. However, these studies have not 
investigated whether these phenotypes in mice lacking A2BAR result from loss of direct 
agonist activation of A2BAR or from loss of an unidentified function of the A2BAR. Ryzhov 
and colleagues (2008a, 2008b) concluded that activation of A2BAR by adenosine results in 
inflammatory effects, consistent with their and others’ previous pharmacological studies. 
However, they also found inflammatory exacerbation in A2BAR knockout mice, such as 
Yang D. (2006) and  Hua (2007) did. Therefore, they have supposed that A2BAR may exert 
an adenosine-independent down-regulation of pro-inflammatory cytokines, possibly by the 
association with other proteins mediated signalling pathways (Ryzhov et al., 2008b). Up to 
now, several proteins such as netrin-1 (Corset et al., 2000), Ezrin/PKA/NHERF-2/E3KARP 
(Sitaraman et al., 2002) and SNARE proteins (Wang et al., 2004) have been reported to 
form a 24 multi-complex with A2BAR. However, all these coupled proteins of A2BAR 
cannot explain the anti-inflammatory role of A2BAR. The apparent low affinity of adenosine 
for A2BRs suggests that this receptor may have important roles in pathological environments 
where adenosine levels are elevated. Taking into account the lack of information about the 
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A2B receptor and its involvement in several inflammatory diseases, it may be a candidate 
target for future therapeutic intervention. 
1.1.6.4 A3AR  
 A3AR appears to have a conflicting role in inflammatory responses, since both pro- and 
anti-inflammatory effects have been demonstrated depending on the cell type and animal 
species being studied (Gessi et al., 2008). Several studies demonstrate that A3AR activation 
produces pro-inflammatory responses. Evidence for a role of A3AR in increasing 
inflammation derives by studies in mast cells where its activation has shown to be 
responsible for release of allergic mediators (Ramkumar et al., 1993). In addition, it has 
been reported that A3AR mRNA is high in lung tissue of patients with airway inflammation 
and that A3AR activation mediates rapid inflammatory cell influx into the lungs of 
sensitized guinea pigs (Walker et al., 1997b; Spruntulis and Broadley, 2001). On the other 
hand, several studies have shown that A3AR activation can have an anti-inflammatory 
effect. For example, in murine BV2 microglial cells, activation of A3AR has suppressed 
LPS-induced TNF-α production by inhibiting phosphoinositide 3-kinase/protein kinase B 
(PI3-k/PKB) and NF-κB activation (Lee et al.,  2006). In sepsis, mice lacking A3AR have 
significantly higher levels of plasma TNF-α, increased mRNA encoding pro-inflammatory 
cytokines, and enhanced nuclear translocation of NF-κB in their renal cortices compared to 
wild type mice (Lee et al., 2006). Similarly, in rheumatoid arthritis patients, the A3AR 
agonist CF502 mediates an anti-inflammatory effect by inhibiting the PI3K/PKB, and NF-
κB signalling pathway (Ochaion et al., 2008). Thus, A3AR can have protective or 
deleterious effect, depending on the cell type involved as well as on the duration of its 
activation. In fact, it is worth noting that both human and rat A3 adenosine receptors are 
desensitized within a few minutes after agonist exposure (Trincavelli et al., 2002), and 
A3ARs are very sensitive to prolonged stress in vitro (Von Arnim et al., 2000). A3AR may 
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be considered as a specific target to control inflammation even if much is still to be learned 
about its role in inflammation.  
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1.2 EXTRACELLULAR ADENOSINE PRODUCERS, 
CD39AND CD73, AND INFLAMMATORY RESPONSE 
CD39 and CD73 represent the predominant pathways of extracellular adenosine production 
as confirmed using genetically manipulated mice (Volmer et al., 2006; Grenz et al., 2007) 
as well as in vitro (Grünewald and Ridley, 2010). Specifically, CD39 catalyses the 
hydrolysis of ATP and ADP to AMP with the liberation of two molecules of inorganic 
phosphates (Pi) and the corresponding nucleoside monophosphate product, AMP,  is then 
degraded to adenosine and phosphate by e-5′NT/CD73 (Zimmermann, 2000). Biological 
actions of NTPDase1/CD39 and  e-5′NT/CD73 are mainly a consequence of their enzymatic 
activity. Importantly, the activity of CD39 is reversible by the actions of nucleoside-
diphosphate kinase (NDP) kinase and AK, whereas the activity of CD73 is virtually 
irreversible. Therefore, e-5′NT/CD73 represents the “peacemaker” enzyme for extracellular 
adenosine production (Hart et al., 2008; Allard et al., 2012). 
1.2.1 Functions and structures 
CD39 belongs to the NTPDase family that consists of eight members (Robson et al., 2006). 
Like NTPDase-2,-3, and -8, NTPDase1/CD39  is located at the surface of the plasma 
membrane (Robson et al., 2006) while NTPDase 4–7 have mainly  intracellular localization 
(NTPDases 5 and 6 can also be present at the surface of the plasma membrane and secreted 
as soluble enzymes) and do not participate in the metabolism of extracellular nucleotides 
(Robson et al., 2006). Millimolar concentrations of divalent cations such as Mg
2+
 and 
Ca
2+
 are essential for nucleotide hydrolysis (Wang and Guidotti, 1996) with maximal 
activity at pH 7.0–8.5 (Kukulski et al., 2005). NTPDase1/CD39 exhibits a substantially 
smaller Km in comparison to the other members of its family, which allows the hydrolysis of 
phosphopurines, ATP and uridine 5’-triphosphate (UTP), at concentrations at least 3 times 
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lower (Kukulski and Komoszynski, 2003; Kukulski et al., 2005). 
NTPDase1/CD39 hydrolyzes ATP almost directly to AMP with the transient production of 
minor amounts of free ADP (Kaczmarek et al., 1996). As consequence, NTPDase1/CD39 
can most efficiently terminate the P2-receptor mediated signalling or prevent its inactivation 
(Kukulski et al., 2011). Structurally, NTPDase1/CD39 is highly glycosylated protein 
characterized by two transmembrane domains, a small cytoplasmic domain comprising the 
NH2 and COOH-terminal segments, and a large extracellular hydrophobic domain. In this 
domain there are five highly conserved sequence domains known as apyrase conserved 
regions, that are crucial for the catalytic activity of the enzyme. NTPDase1/CD39 is firmly 
anchored to the membrane via two transmembrane domains that are important for 
maintaining catalytic activity and substrate specificity (Robson et al., 2006). 
NTPDase1/CD39 becomes catalytically active upon its localization on the cell surface, and 
its glycosylation is crucial for correct protein folding, membrane targeting, and enzyme 
activity (Smith and Kirley, 1998). In addition, it has been demonstrated the presence of 
soluble NTPDase1/CD39 freely circulating in the human and murine bloodstream and 
contributing to the metabolism of intravascular ADP (Coade and Pearson, 1989; Yegutkin et 
al., 2007, 2012). Moreover, NTPDase1/CD39 can be released from pancreatic acini 
(Sorensen et al., 2003), platelets, endothelial cells (Banz et al., 2008; Visovatti et al., 2012), 
and some cancer cells (Clayton et al., 2011) as exosome- or microparticle-embedded 
enzyme.  
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NTPDase1/CD39 was first described as a surface marker of Epstein Barr virus (EBV)-
transformed B cells (Rowe et al., 1982) and proposed to be a cell-surface signalling 
molecule playing a role in the regulation of effector functions of activated lymphocytes 
(Dombrowski et al., 1998). It is expressed in a large variety of tissues including heart, 
placenta, lung, liver, skeletal muscle, thymus, kidney, pancreas, testis, ovary, prostate, colon 
and brain (Zimmermann, 1999). It has been suggested that NTPDase1/CD39 may have 
functions beyond apyrase activity, its localization  within lipid rafts implies that this ecto-
enzyme may be involved in cell-cell contacts and signalling. For instance, NTPDase1/CD39 
can act as an ATP channel (Bodas et al., 2000) or directly interact with Ran-binding protein 
M, a membrane scaffolding protein with guanosine 5’-triphosphate (GTP)ase activity so 
playing a role in intracellular signalling (Wu et al., 2004). 
NTPDase1/CD39 is the dominant NTPDase of the vasculature. Endothelial CD39, by 
converting ADP to adenosine, play an important role in limiting the extent of platelet 
aggregation
. 
(Robson et al., 2005, 2006; Yegutkin, 2008). Accordingly, CD39 knockout 
mice have shown disordered thromboregulation and increased infarct volumes upon 
experimental stroke (Enjyoji et al., 1999;  Pinsky et al., 2002). Recombinant soluble and 
Figure 8. Schematic representation of the NTPDase1/CD39 structure. Modified from  Robson SC, 
Sevigny J, Zimmermann H. (2006) Purin signal. 2:409–30.  
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catalytically active CD39  has demonstrated  to block ADP-induced platelet aggregation  in 
vitro and to inhibit collagen-induced platelet reactivity (Gayle et al., 1998).  
It has been also reported that NTPDase1/CD39 plays important role in modulating the 
inflammatory responses during host–pathogen interactions (Knowles, 2011; Sansom et al., 
2008) and tumorigenesis (Bastid et al., 2012). Several pro-inflammatory cytokines, 
oxidative stress, and hypoxia can affect CD39 expression through the transcription factors 
specificity protein 1, signal transducer and activator of transcription 3, and zinc finger 
protein growth factor independent-1 transcription factor (Eltzschig et al., 2009; Chalmin et 
al., 2012). Moreover, CD39 is upregulated in several solid tumors (colorectal cancer, head 
and neck cancer, pancreatic cancer) as well as in chronic lymphocytic leukemia (Bastid et 
al., 2012).     
e-5’NT/CD73 is the key enzyme in the extracellular adenosine production, indeed 
catalyzing the hydrolysis of AMP to adenosine, it plays a crucial role in “switching on” 
adenosine signalling. Structurally, e-5’NT/CD73 is a glycosyl phosphatidylinositol (GPI) 
anchored membrane protein via a C-terminal serine residue (Ser 523), which belongs to the 
5'-nucleotidase family that includes seven members; other forms of 5’NT exist in the 
cytoplasm and lysosomes and can be distinguished from e-5’NT/CD73 by their substrate 
affinities, requirement for divalent magnesium ion, activation by ATP, and inhibition by 
inorganic phosphate. The enzyme exists as a noncovalent dimer and each subunit (60-74 
kDa) consists of two distinct domains linked by a single α-helix (residues 318–336): an N-
terminal domain (residues 27–317), which binds two divalent metal ions important for 
catalysis, and a C-terminal domain (residues 337–549), responsible for binding the 
nucleotide substrate and by which the enzyme is anchored to the cell membrane (Misumi et 
al., 1990). The active site is created at the interface between the two domains and is formed 
from residues of both domains (Knapp et al., 2012). e-5’NT/CD73 exists in both open and 
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closed conformations. The single α helix comprises a small region, which makes able the 
enzyme to undergo large domain movements and switch between the open and closed 
conformations. Crystal structures of the dimeric human e-5’NT/CD73 show an extensive 
114° conformational switch between the open and closed forms of the enzyme. The 
dimerization interface is formed by the C-terminal domains and exhibits interchain motions 
of up to 13°. The large domain motion,  is required for catalysis (Knapp et al., 2012). This 
enzyme binds Zn
2+
 and other divalent cations which are required for the enzymatic activity 
and 5’-AMP is the preferred physiological substrate (Zimmermann, 1992). The fact that the 
main function of e-5’NT/CD73 is the generation of extracellular adenosine from AMP has 
been confirmed in CD73 knockout mice that show markedly impaired production of 
extracellular adenosine that is not compensated in vivo by other ectoenzymes such as 
alkaline phosphatases (ALP) and acid phosphatases (ACP) or by the release of adenosine 
via ENT. The hydrolysis of 5’-AMP is stereoselective since the L-enantiomer is not a 
substrate. Km values for AMP are in the range of 3-50 μM (Zimmermann, 1992). ATP and 
specially ADP, which are the most common substrates of NTPDases, are potent inhibitors of 
this enzyme (Zimmermann, 1992). Soluble forms of the enzyme have been described 
(Coade and Pearson, 1989; Zimmermann et al., 2012) which are derived from the 
membrane-bound form by hydrolysis of the GPI anchor by phosphatidylinositol-specific 
phospholipase or by proteolytic cleavage (Yegutkin, 2008; Heuts, 2012). A subcellular 
expression of CD73 has been studied intensively in rat liver tissue where the molecule is 
expressed both intracellularly and on the surface of hepatocytes. A similar localization has 
been observed in rat fibroblasts, guinea pig neutrophils, and capillary endothelial cells 
(Widnell et al., 1982; Robinson and Karnovsky, 1983; Zimmermann, 1992).  
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e-5’NT/CD73 was recognized for the first time 82 years ago for its activity in the heart and 
skeletal muscle (Reis, 1934). Independently of its enzymatic role, e-5’NT/CD73 can 
function as a co-stimulatory molecule for T cells, mediate cell-cell adhesion, or may 
regulate cell interaction with extracellular matrix components and migration on them (Airas 
et al., 1995, Airas and Jalkanen, 1996; Airas, 1998; Loertscher  and Lovery, 2002; Andrade 
et al., 2011). It is also considered to be related to the transport process, cellular growth, 
synthesis of fibrous protein and calcification, neurotransmission, and oxygen sensing 
mechanism (Moriwaki et al., 1999).  
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Figure 9. A) Molecular model of e-5’NT/CD73 and  B) the soluble forms derived from it. e-5’NT/CD73 
exists as a dimer of the two subunits linked by at least one disulphide bridge. Soluble forms can exist as dimers 
or tetramers. From Zimmermann H. (1992) Biochem J. 285:345-65. 
 
 
Figure 10.  Human e-5’NT/CD73 crystal structure. From Knapp K, Zebisch M, Pippel J, El-Tayeb A, 
Müller CE, Sträter N. (2012) Structure. 20:2161-73. 
CD73 is expressed in different tissues, including colon, pancreas, salivary glands, brain, 
kidney, liver, lung, heart (Zimmermann, 1992; Zimmermann et al., 2012). It has been 
suggested the importance of CD73 in the diagnosis of inflammatory muscle disease, 
malignancies and hepatobiliary diseases (Sunderman, 1990; Moriwaki et al., 1999) and as a 
marker of both general and local inflammation in rheumatoid arthritis patients (Johnson et 
al., 1999). Hypoxic conditions, as well as interferons, TGF-β1, IL-1β, PGE2 and 
triiodothyronine are capable of inducing cell surface expression of CD73 (Savic et al., 1990; 
B 
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Synnestvedt, 2002; Carneiro-Ramos et al., 2004; Niemelä et al., 2004; Regateiro et al., 
2011). Inflammatory cytokines, such as IL-4, IL-12, Interleukin-21 (IL-21) and IFN-γ, 
counteract CD73 expression induced by TGF-β1 (Regateiro et al., 2011). This suggests that 
inflammatory and anti-inflammatory milieu is important determinant of e-5’NT/CD73 
expression and, therefore, of adenosine levels in the tissues. e-5’NT/CD73 is also up 
regulated in several neoplastic tissues (Beavis et al., 2012). Besides host cells, many 
pathogens (i.e. Toxoplasma gondii, Escherichia Coli) have CD39-CD73-like 
machinery, which helps the pathogen subvert the host inflammatory response.  
1.2.2 CD39 and CD73 in inflammation  
As above mentioned, several studies indicate that the generation of adenosine during the 
inflammatory response is protective functioning as a feedback loop to attenuate potential 
tissue injury. The role of adenosine in “switching off” inflammation has been an area of 
active research; more recently, researchers have focused on the importance of CD39/CD73 
axis during the inflammatory response. Little is known of how NTPD1/CD39 and the e-
5’NT/CD73 are themselves regulated during inflammation. Animals lacking these enzymes 
have revealed their importance in contributing to extracellular adenosine in different organs 
and situations showing circulating nucleotide levels and related pathology (Enjyoji et al., 
1999). In agreement with a lack of their catalytic activity, amplified inflammatory response 
has been observed in CD39 and CD73-deficient mice (Eltzschig et al., 2004; Friedman et 
al., 2009; Reutershan et al., 2009; Haskó et al., 2011).  Interestingly, NTPD1/CD39 and e-
5’NT/CD73 are expressed by a broad range of immune cells, including monocytes, 
neutrophils, fibroblasts, dendritic cells, myeloid-derived suppressor cells, B lymphocytes, 
and some T-cell subsets. CD39 and CD73 can be considered as “immunological switches” 
by removing pro-inflammatory ATP and promoting an anti-inflammatory and immune 
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suppressive milieu (Antonioli et al., 2013). It has recently been observed that CD73 and 
CD39 may also contribute in host inflammatory responses to microbial infection (Yegutkin 
et al., 2010; Haskó et al., 2011; Théâtre et al., 2012).  
1.2.3 Overall effect of CD39 and CD73 on cells of the immune system 
1.2.3.1 CD39/CD73 and neutrophils 
Neutrophils widely express CD39 (Pulte et al., 2007) and, to some extent, CD73 (Flögel et 
al., 2012) that play an important role in regulating their functions (Linden, 2006). There is 
evidence that NTPD1/CD39 and e-5'NT/CD73 limit neutrophil activation, chemotactic 
functions and neutrophil adhesion to the endothelium (Eltzschig et al., 2004; Corriden et al., 
2008; Reutershan et al., 2009; Kukulski et al., 2011). 
1.2.3.2 CD39/CD73 and mononuclear phagocyte system 
It has been established that monocytes and macrophages express CD39 and CD73. CD39  
has found on >90% of human monocytes (Pulte et al., 2007) while only a small percentage 
(about 5%) of human monocytes (CD14
+
CD16
+
) express CD73 on their surface (Sciaraffia 
et al., 2014). This CD14
+
CD16
+
 population of monocytes is increased in some disease 
conditions and is considered to be pro-inflammatory (Ziegler-Heitbrock, 2007). However, 
about 30% of monocytes and macrophages retrieved from the synovial fluid of arthritic 
mice do so (Flögel et al., 2012). Furthermore, in CD73-deficient mice augmented tumor 
immunity has been linked to decreased numbers of intratumoral anti-inflammatory 
macrophages (Yegutkin et al., 2011). Upregulation of IL-1, IL-18, IL-6, TNF-α, tissue 
factor (TF) by these cells, alterations in regulatory macrophage development that leads to 
lethal inflammatory responses and septic shock have been observed in CD39-deficient mice 
(Lévesque et al., 2010).  Zanin and co-workers (2012) have found that, in mice, the pro-
inflammatory phenotype M1 macrophages show reduced expression and activity of both 
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CD39 and CD73, leading to reduced ATP degradation. By contrast, the anti-inflammatory 
phenotype M2 macrophages, show an increased expression and activity of both catabolic 
enzymes, followed quickly by the conversion of ATP into adenosine. Thus, M2 
macrophages generate an adenosine-rich environment, which in turn can augment the anti-
inflammatory and tissue remodeling activities of these cells.  
CD39 and CD73 are also expressed by human monocyte-derived DCs (Berchtold et al., 
1999) and are involved in regulating the recruitment and activation of lymphocytes. 
Extracellular ATP is very rapidly hydrolyzed by DCs thus protecting the cells from ATP- 
induced apoptosis (Girolomoni et al., 1993). Differently to other myeloid leukocytes where 
the expression is developmentally regulated (Clifford et al.,1997), DCs express both 
enzymes during all maturation stages. The expression of CD73 and CD39 by DCs at all 
stages of their differentiation might be important to protect these crucial cells at their 
immature antigen processing stage in the peripheral tissues as well as at their mature, T cell 
sensitizing stage, in the lymphoid organs (Berchtold et al., 1999). TGF induces CD73 
expression in DCs, enabling these cells to generate adenosine within an immune-regulatory 
microenvironment. Mizumoto and colleagues (2002) have established that Langerhans cells, 
DCs residing in the skin, from CD39 knockout mice do not hydrolyze ATP and ADP, unlike 
wild-type cells and that CD39  is required for optimal stimulation of hapten-reactive T cells 
in mice. Moreover, it has been demonstrated that the suppressive action of IL-27 on Th1 and 
Th17 responses is mediated, at least in part, by the induction of CD39 in DCs and the 
resulting accumulation of adenosine (Mascanfroni et al., 2013).   
1.2.3.3 CD39/CD73 and endothelial cells 
CD39 and CD73 are also expressed on endothelial cells. It is well known that CD39 and 
CD73 on endothelial cells regulate leucocyte trafficking (Jalkanen and Salmi,  2008) and 
play a role in the regulation of hemostasis by converting the local environment from a 
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prothrombotic ATP/ADP state, to an antithrombotic, adenosine rich environment (Atkinson 
et al., 2006). Accordingly, alterations in the expression and activity of CD39 or CD73 result 
in disordered hemostasis and thromboregulation (Enjyoji et al., 1999; Koszalka et al., 
2004). CD39 and CD73 are known to play an important role in leukocyte 
trafficking  (Linden, 2006; Eltzschig et al., 2004). In areas of ongoing inflammation, CD39 
and CD73 expressed on the surface of endothelial cells, coordinate the metabolism of ATP 
to adenosine. Activated PMNs are a source of extracellular ATP that through two enzymatic 
steps results in the liberation of adenosine. Activated platelets constitute an additional 
source of extracellular adenosine. Adenosine generated, can activate surface endothelial 
adenosine receptors, particularly the A2BAR that enhances endothelial barrier function. 
These findings identify CD39/CD73 pathway as a protective innate mechanism to preserve 
the vascular integrity and to prevent intravascular fluid loss (Eltzschig et al., 2004). It has 
been shown that leukocyte binding on endothelial cell triggers the inhibition of CD73 
activity, thereby reducing local adenosine production which favors vascular permeability 
and leukocyte transmigration (Henttinen et al., 2003). The importance of CD73 and CD39 
on endothelial cell function has been largely evidenced by studies performed on mice 
lacking these enzymes. CD73 and CD39-deficient mice present an increased accumulation 
and adhesion of leukocytes to the vascular endothelium (Eltzschig et al., 2004, Petrovic-
Djergovic et al., 2012; Takedachi et al., 2008). In contrast to its role in vascular 
endothelium, CD73 does not affect the permeability of lymphatic endothelium (Ålgars et 
al., 2011). It has been demonstrated that CD73 normally suppresses pro-inflammatory 
responses in human endothelial cells, indeed its depletion induces a similar response to pro-
inflammatory stimuli such as the cytokine TNF-α, consisting in high levels of the leukocyte 
adhesion molecules Intercellular Cell Adhesion Molecule Type 1 (ICAM-1), VCAM-1 and 
E-selectin (Grünewald and Ridley, 2010). interferons (IFNs) I and II increase CD73 
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expression at the surface of endothelial cells, thus promoting adenosine generation and 
subsequent enhancement of endothelial cell barrier (Niemelä et al., 2004, 2008). In contrast, 
TNF-α may reduce the capacity of human endothelial cells to produce adenosine by 
reducing CD73 surface expression and activity; probably this could be an important 
mechanism of endothelial activation during inflammation (Kalsi et al., 2002).  
1.2.3.4 CD39/CD73 and lymphocytes 
Originally, CD39 and CD73 have been identified as markers of  B cell activation (Rowe et 
al., 1982; Resta et al., 1998). Subsequently, their expression has also been demonstrated on 
resting B cells (Saze et al., 2013). On lymphocytes, CD73 and CD39 represent a maturation 
marker, being absent from the surface of both immature B and T cells (Thompson et al., 
1986; Heilbronn and  Zimmermann, 1995) and increasing their expression during T and B 
cell development. It has been  demonstrated that human circulating B cells co-express CD39 
and CD73 and  adenosine receptors (ARs). Interestingly, in human B cell line, it has been 
observed a coordinated expression of A2AAR and CD73 (Napieralski et al., 2003). Recently, 
Schena and co-workers  (2013) have shown that ATP is stored in secretory vesicles in 
human B cells and that may be released upon B cell receptor stimulation. This ATP may be 
hydrolyzed to adenosine by CD39 and CD73 expressed on B cells, inducing an autocrine 
adenosine signalling which facilitates immunoglobulin diversification via class switch 
recombination, an essential process in mounting a humoral immune response. Accordingly, 
patients with impaired class switching antibody responses present B cells deficient in CD73 
expression (Schena et al., 2013). Moreover, CD39 and CD73 are highly expressed in murine 
CD4
+
 Foxp3
+
 Treg cells and have been widely used as markers of this T-cell 
subpopulation (Kobie et al., 2006; Deaglio et al., 2007). CD73 and CD39 expression is 
augmented upon TCR engagement. Human Treg cells express CD39 on their surface, but in 
contrast to murine Treg cells, CD73 is mainly localized in the cytosol (Mandapathil et al., 
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2010). It has been suggested that CD73 is secreted from human Tregs and that in this form 
is able to convert AMP to adenosine (Antonioli et al., 2013). It is thought that CD39 allows 
the entrance of Treg cells into inflamed regions, where high levels of ATP are present and 
subsequently it confers protection against ATP-induced apoptosis. Adenosine produced in 
tandem by CD39 and CD73 locally by Tregs inhibits the activation of effector T cells and 
APCs through A2A receptors (Deaglio et al., 2007; Romio et al., 2011). In addition, 
adenosine stimulating A2A receptors, expressed on Tregs, elicits their expansion and 
increases their immunoregulatory activity (Ohta et al., 2012). Thus, dual expression of 
CD39 and CD73 not only serves as a phenotypic marker for Tregs, but also provides an 
autocrine feedback loop to enhance the anti-inflammatory functions of this subset of T cells. 
CD73 is also expressed by Th primed precursor (Thpp) cells (Yang et al., 2005; Kobie et 
al., 2006) that can produce adenosine and suppress the proliferation of CD4
+ 
or CD8
+ 
T cells 
(Kobie et al., 2006). 
Although Th17 cells are known to promote tissue inflammation and autoimmunity,  in vitro 
Th17 cells generated with the cytokines IL-6 and TGF-β, that are crucial for Th17 cell 
development, express  CD39 and CD73 which, by producing adenosine, suppress T cell 
activation (Chalmin et al., 2012). Interestingly, such a function has been found only in Th17 
cells induced by TGF-β plus IL-6, whereas those induced in the absence of TGF-β are not 
immunosuppressive. TGF-β - induced CD73 activity may be responsible for this difference. 
Additionally, in human and mice, CD39 is also expressed on pre-existing memory T cells of 
Th1-, Th2- and Th17-types with heightened alloreactivity (Moncrieffe et al., 2010; Zhou et 
al., 2009). It has been proposed that CD39 expression by memory T cells may contribute to 
“switch off” the ongoing inflammation and/or to save these cells from ATP-induced 
apoptosis/necrosis (Zhou et al., 2009). 
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Murine NK cells abundantly express CD39 mRNA, but very little CD73 mRNA; their 
presence suggests that extracellular adenosine can be produced during inflammation and 
modulate immune function. It has been reported that mice lacking CD39 are protected from 
acute vascular injury after hepatic ischemia/reperfusion injury because CD39 loss and 
alteration in ATP receptors activation abolish secretion of IFN-γ by NK cells in response to 
inflammatory mediators, therefore limiting tissue damage (Beldi et al., 2010). In the liver, 
CD39 is not expressed by quiescent sinusoidal endothelial cells (Beldi et al., 2010). In 
contrast, in organs, such as the kidney, where CD39 is highly expressed by the endothelium, 
it has been shown to be protective in ischemia/reperfusion injury. In resting human NK 
cells, the expression of CD39 is reported to be very low (~5%) (Pulte et al., 2007). NKT 
cells co-express CD39 and CD73 and  it has been shown that knockout mice for CD39 are 
protected from Con A-induced hepatitis by increasing NKT apoptosis and modulating 
cytokine secretion in vivo (Beldi et al., 2008).   
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1.3 ADENOSINE SIGNALLING AND ANTI-
INFLAMMATORY DRUGS 
Interestingly, adenosine signalling pathway has also been shown to be required for the 
biological effect of several drugs that modulate the inflammatory/immune response. Indeed, 
there is evidence that CD73 is required for the anti-inflammatory effect of methotrexate 
(Montesinos et al., 2007); furthermore, the beneficial effect of  IFN- in patients affected by 
multiple sclerosis has been associated to CD73 upregulation at the blood-brain barrier 
(Niemelä et al., 2008); evidence shows that the anti-inflammatory effects of aspirin involves 
also adenosine accumulation, independently from cyclooxygenase (COX) inhibition 
(Cronstein et al., 1999). It has also revealed CD73 involvement in the beneficial effects 
exerted by statins (Meijer et al.; 2009, 2010) that, originally developed to improve lipid 
profile, have demonstrated a surplus of beneficial pleiotropic effects, including reduced 
inflammation. Very recently, it has been shown that in mice the anti-arthritic effect of 
exogenously administered fructose 1,6–biphosphate, an endogenous intermediate of 
glycolysis, involves  CD39/CD73/adenosine signalling pathway (Veras et al., 2015).  
1.3.1 Nimesulide  
Nimesulide (N-(4-Nitro-2-phenoxyphenyl)-methane sulphonamide; Figure 11) is a Non-
steroidal anti-inflammatory drug (NSAID), with a unique chemical structure, belonging to 
the sulphonamides class.  
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Figure 11.  Chemical structure of nimesulide 
Nimesulide has anti-inflammatory as well as antipyretic and analgesic activities. Like all 
NSAIDs, nimesulide blocks the biosynthesis of  PGs starting from arachidonic acid, by 
inhibiting the enzyme COX. The clinical use of NSAIDs far preceded the characterization 
of their molecular target, the COX enzyme, that was identified by Vane Jr in 1971. In the 
early 1990s, a second isoform (COX-2) was discovered, distinct from the first one, then 
renamed cyclooxygenase-1 (COX-1) (Xie et al., 1991). COX-1 is constitutively expressed 
in most cells and elaborates beneficial “housekeeping” prostaglandins involved in various 
physiological processes, i.e. maintaining gastromucosal integrity, renal function and platelet 
aggregation, whereas COX-2 is induced by pro-inflammatory cytokines, tumor promoters 
and mitogens, at sites of inflammation/tissue injury; prostaglandins formed via COX-2 
enzyme mediate pain, inflammation, fever (Seibert et al., 1994). However, recent 
discoveries call this paradigm into question and reveal unappreciated functions for both 
enzymes; for instance, recent studies have shown that COX-1 may contribute to the 
inflammation processes whereas COX-2 is constitutively expressed in several tissues and 
organs such as the brain, kidneys, endothelium and reproductive tissues. In addition, using a 
model of carrageenan-induced pleurisy in rats, Gilroy  and colleagues (1999) have shown 
that COX-2 has a pro-inflammatory role in the early phase but an anti-inflammatory role in 
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the later phase of inflammation. The anti-inflammatory role has been associated with the 
production of cyclopentenone prostaglandins (prostaglandin D2 (PGD2) and 15 deoxyΔ
12-
14
PGJ2) and the absence of PGE2 (Gilroy et al., 1999). 
 
Figure 12.  The Arachidonic Acid cascade. From Nathan C. (2002) Nature. 420:19-26. Various pathways 
lead to the formation of eicosanoids. The first step in their biosynthesis is the production of free arachidonic 
acid in tissues from membrane phospholipids upon stimulation of the enzyme phospholipase A2 or from the 
hydrolysis of diacylglycerol by diacylglycerol lipase. There are then three main enzymatic cascades for 
eicosanoid formation, involving cyclooxygenases, lipoxygenases, and enzymes of the cytochrome P-450 
family.                     
Human COX-1 and COX-2 are heme-dependent enzymes, membrane bound in the nucleus 
and endoplasmic reticulum  in all cells except the erythrocytes. They are  homodimers of 
576 and 581 amino acids respectively, that show a high sequence homology (60%). 
Possessing two separate but linked active sites, the COXs catalyze the bis-deoxygenation 
and subsequent reduction of arachidonic acid (AA) to (PG) G2 and PGH2. Each subunit of 
the dimer consists of three domains, the epidermal growth factor domain (residues 34–72), 
the membrane binding domain (residues 73– 116), and the catalytic domain comprising the 
bulk of the protein, which contains the cyclooxygenase and peroxidase active sites on either 
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side of the heme prosthetic group. The cyclooxygenase active site is created by a long 
hydrophobic channel that is the site of  NSAIDs binding. The arachidonate binding site is 
located in the upper half of the channel, from Arginine (Arg)-120 to near  Tyrosine (Tyr)-
385. The most significant difference between the isoenzymes is the substitution 
of  isoleucine  at position 523 in COX-1 with valine in COX-2. The smaller Val523 residue 
in COX-2 allows access to a hydrophobic “side-pocket” resulting in a larger (about 20%) 
and more accessible channel, in COX-2 (which Ile523 sterically hinders) that can 
accommodate bulky groups such as the methyl sulphonyl moiety of nimesulide. Indeed, 
nimesulide is a preferential COX-2 inhibitor (Famaey, 1997; Bennett and Villa, 2000). 
 
Figure 13.  Differences in the NSAIDs binding sites of COX-1 and COX-2. 
The therapeutic action of NSAIDs is produced by the inhibition of COX-2, while the 
undesired side effects occur from inhibition of COX-1 activity. It has been also 
characterized a COX enzyme, designated as cyclooxygenase-3 (COX-3), in dog brain 
which, unlike COX-1 and COX-2, is sensitive to inhibition with paracetamol. COX-3, is a 
65-kDa membrane protein whose cyclooxygenase activity is about 80% lower than that of 
COX-1. Preferential expression of COX-3 in the brain and heart has been reported. COX-3 
is considered to play a key role in the biosynthesis of prostanoids known to be important 
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mediators in pain and fever. Drugs that preferentially block COX-1 also appear to act on 
COX-3. 
Nimesulide was invented by Dr. George Moore (a medicinal-organic chemist), Dr. Karl F 
Swingle (a pharmacologist), Dr.  Bob Scherrer (a medicinal chemist) and their colleagues at 
Riker Laboratories Inc (Northridge, California, US, later part of the 3M Company at St 
Paul, Minnesota, US) in 1971. They aimed at finding a molecule to achieve oxyradical 
scavenging on the concept that free radicals are critical factors in chronic inflammatory 
disease. Since its first launch in 1985 in Italy as Aulin® and Mesulid®, nimesulide has been 
extensively used in Europe, South America and Asia; it has never been approved in USA, 
Japan, UK, Germany and Canada. It is available in a variety of forms: capsules, tablets, 
powder or granules for oral suspension, suppositories, mouth dissolving tablets and topical 
gel. Nimesulide has a relatively rapid onset of action, with significantly reductions in pain 
and inflammation observed within 15 minutes from drug intake, it has been the primary 
treatment choice for a rapid anti-inflammatory and analgesic effect (Rainsford, 2006). 
Nonetheless, in Spain, Finland, Belgium and Ireland nimesulide has been withdrawn from 
the market following reports of serious liver damages. A recent evaluation from 
the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines 
Agency (EMA) has concluded that the overall benefit/risk profile of nimesulide is 
favourable and in line with that of the other NSAIDs such as diclofenac, ibuprofen, 
and naproxen; but that there is a need to limit the duration of use to minimize the risks 
associated with nimesulide as hepatotoxicity (Franchi et al., 2015). The mechanism 
subtended to nimesulide hepatotoxicity is not known, it is thought that is an example of 
idiosyncratic drug toxicity. Most cases resolve in few days after stopping therapy. However, 
multiple instances of acute liver failure with death or need for emergency liver 
transplantation have been described. Current indications limit nimesulide use with a 
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prescription as a second line treatment of acute pain where acute inflammation is the most 
predominant component and primary dysmenorrhea for which the recommended dose is 100 
mg twice daily for no more than 15 days in adolescents and adults above 12 years old. The 
use of nimesulide is contraindicated in patients with known hepatic impairment, during third 
trimester of pregnancy and in breast feeding women. Unlike other classical NSAIDs, it has 
high gastro tolerability due to its relatively high pKa value (6.5) and preferential COX-2 
selectivity (COX-2/COX-1=0.19; Famaey, 1997; Bennett and Villa, 2000). Nimesulide is 
generally well tolerated, adverse effects are mainly gastrointestinal (diarrhea, heartburn, 
nausea, loose motions); dermatological (rash, pruritus); and central (somnolence, dizziness) 
(Bjarnason et al., 2005). Nimesulide is well absorbed from the gastrointestinal tract 
following oral administration. The presence of food did not reduce either the rate or extent 
of nimesulide absorption. When nimesulide is administered in the suppository form, the 
Cmax is lower and occurs later than after oral administration; the bioavailability of 
nimesulide via suppository ranged from 54 to 64%, relative to that of orally administered 
formulations. Around 99% is bound to plasma protein. Nimesulide undergoes extensive 
hepatic biotransformation, mainly to 4-hydroxynimesulide (which also appears to be 
biologically active). Minor metabolites have been detected in urine and faeces. The 
elimination half-life varies from  2 to 5 hours (Bernareggi, 1998). Since nimesulide is 
extensively bound to plasma proteins it can be displaced from binding sites by concurrently 
administered drugs such as fenofibrate, salicylic acid and tolbutamide. Nimesulide causes 
enzymatic induction of theophylline when administered concomitantly with it and reduces 
the diuretic effect of concomitantly administered furosemide (Perucca, 1993).  
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1.3.2 Nimesulide as atypical non-steroidal anti-inflammatory drug 
(NSAID) 
Nimesulide is a unique drug, different from both non-selective and selective COX-2 
inhibitors, not only due to its chemical structure. Indeed, while selective COX-2 inhibitors 
increase the risk for cardiovascular diseases, nimesulide does not exert significant 
cardiotoxicity. In addition, nimesulide has been shown to inhibit cancer cell proliferation 
(Shaik et al., 2004; Liang et al., 2009), to protect rats from cerebral ischemia (Candelario-
Jalil, 2008) and to protect from NSAIDs-induced ulcers (Süleyman et al., 2002). Nimesulide 
has potent anti-inflammatory activity. Its mechanism of action is multifactorial with a 
unique and broad action on the inflammatory process which targets different pathways. Like 
all NSAIDs, nimesulide inhibits the synthesis of prostaglandins, chemical messengers that 
mediate inflammation. In addition, nimesulide has shown a variety of effects that are not 
due to COX-2 inhibition including: 
 Reduction of toxic oxygen metabolites generation by stimulated PMNs (Ottonello et 
al., 1993; Bevilacqua et al., 1994). 
 Inhibition of histamine release and action (Rossoni et al., 1993). 
 Inhibition of collagenase and other metalloproteinases activity(Pelletier et al., 1993). 
 Inhibition of LTB4 and C4 release (Tool et al., 1996). 
 Inhibition of PAF production by activated cells  (Tool et al., 1996). 
 Inhibition of urokinase synthesis (Pelletier et al., 1997). 
 
 Inhibition of cytokine release  such as TNF-α, IL-6 (Pelletier et al., 1997). 
 Phosphorylation and activation of glucocorticoid receptors (Pelletier et al., 1999). 
 Reduction of neutrophils adherence and receptor expression (Rainsford and 
Members of the Consensus Report, 2006). 
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 Inhibition apoptotic process in connective tissue cells (Rainsford and Members of 
the Consensus Report, 2006). 
 Inhibition of nitric oxide synthases (NOS) enzyme (Rainsford and Members of the 
Consensus Report, 2006). 
Thus, the ability of nimesulide to affect so many relevant mediators in inflammation confers 
its potent anti-inflammatory activity with a biochemical mechanism that has not been 
elucidated at all, but it goes beyond COX-2-dependent prostaglandin synthesis inhibition. 
However molecular mechanisms at the basis of nimesulide peculiar pharmacological effects 
are still unclear (Rainsford, 2006). 
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1.4 ADENOSINE/A2A SIGNALLING AND FGF-2 
1.4.1 Adenosine: a link between inflammation and wound healing 
Inflammation is regarded as a key step in wound healing. Wound healing is a complex 
process involving soluble mediators, blood cells, extracellular matrix and parenchymal cells 
(Singer and Clark, 1999 ; Bullers et al., 2012). The process of inflammation to the wound 
healing is divided into three phases: 1) inflammation process  that includes also hemostasis 
phase that represents the immediate response; 2) tissue formation and 3) tissue remodeling 
(Eming et al., 2007). Inflammatory cells are present during each of the phases of wound 
repair.  Neutrophils, circulating monocytes that differentiate into mature tissue macrophages 
and mast cells are predominant in the early-stage. Cytokines, chemokines, growth factors,  
NO and large amounts of ROS produced by infiltrating immune cells during early 
inflammatory phase set the stage for tissue repair. In the late inflammatory phase of wound 
repair, T lymphocytes appear in large number in the wound with M2 macrophages. 
As inflammation resolves and the number of leukocytes diminishes, the wound undergoes a 
lengthy period of remodeling and resolution (Koh and Di Pietro, 2011). 
Persistent or exacerbated inflammation may interfere with wound healing by impairing the 
quality of healing. Complete resolution of an acute inflammatory response and the return of 
the local tissues to homeostasis are necessary for activation of subsequent steps of wound 
healing process. The overall balance of the pro and anti-inflammatory signals determine if 
the wound  progresses to a chronic state.  
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Figure 14.  Different Phases of Wound Healing. From Shaw T, Martin P. (2009) J of Cell Sci 122:3209-13. 
A) Immediate response B) Inflammatory response C) Proliferative phase D) Remodeling/Maturation Phase. 
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As already reported, adenosine during inflammation and tissue destruction is released into 
the extracellular space and acts as a negative regulator of both inflammation and immune-
mediated tissue destruction. A2A receptor has been described to be anti-inflammatory in 
several models of acute and chronic inflammation. Furthermore, the same receptor is also 
involved in adenosine-mediated wound healing. Montesinos and co-workers (1997) first 
reported that topical application of adenosine A2A receptor agonists promotes more rapid 
wound healing in full-thickness dermal wounds in both normal mice  and  streptozotocin- 
induced diabetes mellitus rats, this effect is reversed by selective A2AAR  antagonists. Later 
studies using mice lacking A2AAR and selective A2A agonists confirmed that A2A is the 
adenosine receptor most involved in promoting wound healing (Montesinos and Cronstein,  
2001; Victor-Vega et al., 2002). It has been demonstrated that adenosine A2A receptor 
activation promotes fibroblast migration in vitro and increases matrix production and 
fibroblast infiltration into the wounds (Montesinos et al., 1997). Moreover, adenosine 
promotes angiogenesis in vitro and in vivo both directly and indirectly by stimulating 
vascular endothelial growth factor (VEGF) production by macrophages and endothelial cells 
and by suppressing production of the antiangiogenic factor thrombospondin 1 (Leibovich et 
al., 2002; Montesinos  et al., 2002; Desai et al., 2005). In addition to directly stimulate 
collagen production by fibroblasts (Chan et al., 2006), adenosine also favors collagen 
production by promoting recruitment of bone marrow-derived fibrocytes from the 
circulation. In some situations, collagen production following adenosine A2A receptor 
stimulation can be a two-edged sword; mice treated with subcutaneous bleomycin develop 
diffuse dermal fibrosis and both A2AAR knockout mice and mice treated with a selective 
A2AAR antagonist are protected from the development of bleomycin-induced dermal 
fibrosis (Chan et al., 2006); in addition, mice lacking  adenosine deaminase show diffuse 
dermal fibrosis, which is blocked by adenosine A2A receptor blockade (Fernández  et al.,  
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2008). It is interesting to note that A2AAR activation modulates the functions of all the 
inflammatory cells observed at the site of a wound; adenosine, acting at its receptors, can 
suppress the pro-inflammatory functions of these cells so decreasing their deleterious effects 
and transform a potentially destructive response to regeneration response by increasing local 
vascularization and extracellular matrix deposition.  
1.4.2 Fibroblast growth factor-2 (FGF-2) 
Fibroblast growth factor-2 (FGF-2) also termed basic FGF (bFGF), is a small peptide 
belonging to the FGF family of heparin-binding growth factors (FGFs) that consists of 23 
members. FGF-2 contains  four cysteine  residues at amino acids 26, 70, 88 and 93  with no 
intramolecular disulfide bonds, a large number of basic residues, and two sites (Ser 64 and 
Thr 112) that can be phosphorylated by PKA and C, respectively (Bikfalvi et al., 1997). 
Cysteines at 26 and 93 are conserved while those at 70 and 88 are absent or located 
elsewhere in other FGFs (Arakawa et al., 1989). FGF-2 consists of 12 anti-parallel -sheets 
organized into a trigonal pyramidal structure. FGF-2 exists in five different molecular 
weight isoforms: 18-kDa or low molecular weight (LMW) FGF-2, and 22-, 22.5-, 24- and 
34-kDa or high molecular weight (HMW) FGF-2. The HMW forms derive from alternative 
translation initiation (CUG) codons and contain the complete LMW sequence in addition to 
an NH2-terminal extension of varying length (Moscatelli et al., 1987; Sommer et al., 1987; 
Florkiewicz and Sommer, 1989; Prats et al., 1989; Okada-Ban et al., 2000). These isoforms 
are equally active, but while the HMW isoforms are predominantly localized to the nucleus 
and are not secreted, the 18-kDa form is mainly cytoplasmic and can also be released by 
cells (Bugler et al., 1991; Florkiewicz et al., 1991; Mignatti et al., 1991; Renko et al., 
1990). 18-kDa is released from cells through an unclear mechanism that is independent of 
the endoplasmic reticulum (ER)-Golgi system lacking a classical signal peptide and 
involves exocytosis and requires ATP (Mignatti  et al., 1992; Florkiewicz  et al., 1995). The 
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release seems to be mediated by vesicle shedding at the plasma membrane or following cell 
damage (Taverna et al., 2003). Moreover, while 18-kDa form acts through activation of cell 
surface FGF-receptors, the HMW (22, 22.5, 24 and 34 kDa) FGF-2s signal independently of 
FGFR.  In addition to inducing FGF receptor signal transduction, bound 18 kDa FGF-2 can 
be internalized, either in association with heparan sulfate or its receptor. Once internalized, 
FGF-2 can be degraded, possibly into 4-10 kDa bioactive fragments, or translocated to the 
nuclear fraction of various cell types as a receptor-ligand complex (Hawker and Granger, 
1992; Clarke et al., 2001). As above mentioned, HMW forms of FGF-2 are associated with 
nuclear translocation. Entry into the nucleus is associated with FGF-induced effects such as 
casein kinase II activation, which is necessary for cell-cycle progression and proliferation. 
FGF-2 is generally readily sequestered to the extracellular matrix, as well as the cell surface, 
by heparin sulphate proteoglycans (HPSGs). FGF-2 is released from the extracellular matrix 
by heparinases, proteases or specific FGF-binding proteins, and the liberated FGF-2 
subsequently bind to cell surface HPSGs. The biological activity of extracellular FGF-2 is 
mediated through a dual receptor system consisting of five high-affinity, tyrosine kinase 
receptors  (FGFR-1 (flg), FGFR-2 (bek), FGFR-3, and FGFR-4, FGFR-6) and low-affinity, 
heparin and heparan sulfate proteoglycans located at the cell surface (Moscatelli, 1987; 
Flaumenhaft et al., 1989; Lee et al., 1989; Dionne et al., 1990; Keegan et al., 1991; 
Partanen et al., 1991; Okada-Ban et al., 2000). A sixth receptor, FGFR-5 (also known as 
FGFRL1), can bind FGF-2, but has no tyrosine kinase domain, and might negatively 
regulate signalling (Wiedemann and Trueb, 2000). However, it has been suggested that also 
intracellular FGF-2 might have a direct biological role, particularly within the nucleus. 
Heparin and cell surface heparan sulfate seem to dimerize monomeric FGF-2 that is 
subsequently able to dimerize and activate FGF receptors (Ornitz, 2000). It has been shown 
that heparin and heparan sulfate can also inhibit FGF-2 receptor binding and activity. Cells 
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that do not express heparin-like glycosaminoglycans show reduced receptor binding affinity 
and reduced biological response. However, it has been reported that FGF-2 may be able to 
signal in the absence of  heparin-like glycosaminoglycans (Padera et al., 1999). Several cell 
types express fibroblast growth factor receptors (FGFRs) including fibroblasts, monocytes, 
macrophages, endothelial cells, keratinocytes, vascular smooth muscle, hematopoietic 
progenitors and epithelial cells. The FGFRs consist of three extracellular immunoglobulin 
(Ig) domains, a single transmembrane helix, and an intracellular split tyrosine kinase 
domain. The second and third Ig domains form the ligand-binding pocket and have distinct 
domains that bind both FGF-2 and HSPGs  (Turner  and Grose, 2010). FGF receptors signal 
as dimers and ligand-dependent dimerization leads to a conformational shift in receptor 
structure that activates the intracellular kinase domain, resulting in intermolecular 
transphosphorylation of the tyrosine kinase domains and the intracellular tail. 
Phosphorylated tyrosine residues on the receptor function as docking sites for adaptor 
proteins, which themselves may also be directly phosphorylated by FGFRs, leading to the 
activation of multiple signal transduction pathways including RAS–RAF–MAPK, PI3K–
PKB, signal transducer and STAT and PLCγ (Turner  and Grose , 2010). FGFRs have also 
been shown to bind and directly phosphorylate ribosomal S6 kinase. Signalling can be 
negatively regulated at several levels by receptor internalization or by the induction of 
negative regulators, including FGFR-L1, SPRY, (CBL), MAPK phosphatase 1 and 3 
(Turner  and Grose, 2010).  Therefore, FGF-2 is a molecule with autocrine, paracrine and 
intracrine signalling mechanisms. 
First discovered to stimulate the proliferation of fibroblasts (Holley and Kiernan, 1968) and 
isolated from bovine pituitary extracts by Armelin (1973) and then found in a cow brain 
extract by Gospodarowicz and colleagues (1975), subsequently, FGF-2 has been isolated 
from  many tissues and cell types including visceral and vascular smooth muscle cells, 
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cardiac muscle cells, lining epithelium of the colon and bronchus, neurons, plus cerebellar 
Purkinje cells, megakaryocytes and platelets, endothelial cells, mast cells, glomerular 
parietal epithelial cells and podocytes, astrocytes, CD4
+ 
and CD8
+
 T cells, fibroblasts (plus 
extracellular matrix), and numerous embryonic mesodermal and neuroectodermal tissues.  
The HMW FGF-2 expression may be absent or restricted even in tissues that produce FGF-2 
protein. For example, in human epiphyseal growth plate cartilage, HMW FGF2 is expressed 
only in proliferating chondrocytes in contrast to LMW FGF-2. For a long time, FGF-2 has 
been known to only initiate fibroblasts proliferation. It is now proved that FGF-2 induces 
proliferation of many other cells including endothelial cells, cortical neurons, mesenchymal 
stem cells that can differentiate into mesenchymal lineages, including osteoblasts, 
chondrocytes, and adipocytes, smooth muscle cells (Raballo et al., 2000; Ahn et al., 2009). 
The function of FGF-2 is not restricted to cell growth. Recently, FGF-2 has been shown to 
affect differentiation, mobility, and survival of several cell types including fibroblasts, 
osteoblasts, smooth muscle cells, and neuroblasts. There is now evidence that FGF-2 is 
implicated in many biological processes including angiogenesis, embryonic development 
(brain, limb, lung, heart, muscle, bone, blood, eye and skin) wound healing and 
inflammation (Dono et al., 1998; Ortega et al., 1998; Montero et al., 2000; Böttcher and 
Niehrs, 2005; Jeon et al., 2007; Presta et al., 2009).  
1.4.3 FGF-2 and inflammation 
Inflammation and wound healing are closely integrated processes. As already mentioned, 
FGF-2 is a powerful mitogen for fibroblasts and plays a crucial role in wound healing. 
Fibroblasts are actively involved in the resolution of inflammation. Beside fibroblasts, other 
inflammatory cell types can express FGF-2, including mononuclear phagocytes, CD4
+
 and 
CD8
+
 T lymphocytes, and mast cells. Several studies have shown that there is an increased 
expression of FGF-2 in inflamed tissues; high levels of FGF-2 have been found in 
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bronchoalveolar lavage fluids from asthmatic subjects, in inflammatory bowel disease and 
in synovial fluid in severe rheumatoid arthritis (Manabe et al., 1999; Kanazawa et al., 2001; 
Redington et al., 2001). It has been proved that interferon IFN-α plus IL-2, IL-1β , and NO 
increase FGF-2 production and release (Cozzolino et al., 1993; Walford and Loscalzo, 
2003; Lee et al., 2004c). Therefore, it has been suggested that FGF-2 is involved in the 
modulation of the inflammatory processes. Griffioen and colleagues (1996) have 
demonstrated the inhibition of cell adhesion molecules expression on Human Umbilical 
Vein Endothelial Cells (HUVECs) pre-treated with FGF-2 for 3 days.  Zhang and Issekutz 
(2001) have confirmed these data showing that treatment for 24 hours or longer 
downregulates the expression of ICAM-1, VCAM-1, and monocyte chemotactic protein 1 
(MCP-1) protein production, in addition, they have found  that FGF-2 treatment  of  
HUVECs  for 18 hours temporarily increases expression of  ICAM-1 and VCAM-1, but not 
E-selectin,  in response to a variety of stimuli including cytokines. Therefore, they have 
suggested that FGF-2 may be an important positive regulator of leukocyte recruitment in 
acute inflammation and an anti-inflammatory regulator during chronic inflammation. 
Human recombinant basic fibroblast FGF-2 has shown to inhibit croton oil-induced ear 
swelling and carrageenan-induced paw oedema in mice and to reduce peritonitis induced by 
carrageenan in mice and rats by inhibiting NOS activity, by reducing NO, malondialdehyde, 
and PGE2 content and  by increasing  superoxide dismutase (SOD) activity (Hu and Wu, 
2001). Moreover, in a murine model of asthma, recombinant FGF-2 has been shown to 
reduce airway responsiveness, mucus production, and lung inflammation and also to reduce 
allergen-induced proliferation of T cells (Jeon et al., 2007). Although different studies 
suggest FGF-2 involvement in the inflammatory process, its role in inflammation is still 
unclear.   
 
Figure 1. A primer of the inflammatory cascade. Adapted from Noah TA, Zachary M, Weil, Randy JN. 
(2012) Annu Rev Ecol Evol Syst. 43:385–406.  Inflammation is induced by pathogens, tissue injury, and 
foreign particles (a). The first step of the inflammatory cascade is the recognition of infection or damage 
(b) that is generally accomplished by the detection of pathogen-associated molecular patterns (PAMPs), or 
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1.5 AIM OF THE STUDY 
 
On the basis of a large amount of literature, as described, the CD39/CD73/adenosine axis is 
an important pathway that sense inflammation. Adenosine affects several cellular functions 
through the interaction with its receptors; for a long time the attention of researchers has 
been focusing on this molecule and its receptors and to date some functions of adenosine 
receptors have been clear revealed while for others remains a certain ambiguity. More 
recently, scientists have shifted their focus toward the two enzymes leading adenosine 
generation from ATP, but without losing sight of adenosine and its receptors; thus moving 
from the role of “adenosine in inflammation” toward the role of  “CD39/CD73/adenosine 
axis in inflammation”. Thus, it is clear as such a change of point of view confers importance 
to this pathway in the control of the inflammatory/immune response. In this respect, it is 
very important to keep in mind that inflammation is not a “self-confined” pathology but it is 
closely related to tumour, thrombosis, fibrosis and other diseases. Thus, it is easy to 
understand as CD39/CD73/adenosine axis has a place in several disorders. This has been 
further corroborated by evidence that several drugs, targeting different diseases all related to 
inflammation, affect CD39/CD73/adenosine axis.  
To date, the anti-inflammatory therapy is mainly based upon an approach directed to inhibit 
inflammatory mediators. However, it is worth considering that inflammation, being a self- 
limiting process, is regulated by pro- and anti- inflammatory mediators, among the latter 
mediators, adenosine plays a role. On this basis, a better knowledge on the role of 
CD39/CD73/adenosine signalling within the network of molecules orchestrating the 
inflammatory response will help to consider different approaches to face inflammation, 
based on the stimulation of an endogenous anti-inflammatory pathway.  
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The aim of the present research work was to explore different aspects of adenosine 
signalling pathway in inflammation. We have first considered the role of CD73, the key 
enzyme in “switching on” adenosine signalling, in the development of  inflammation using 
an in vivo model of  inflammation represented by carrageenan-induced pleurisy in rats, a 
useful model to study the acute and the subacute phase of the inflammatory process.  
As already described, the role of adenosine signalling pathway in the control of 
inflammation has been growing further following evidence that adenosine signalling is also 
involved in the mechanism of action of some well-known anti-inflammatory drugs. With 
regard to this, we focused our interest on the possible involvement of adenosine signalling 
on nimesulide anti-inflammatory effect. Indeed, nimesulide, among all COX-2 selective 
inhibitors, shows some peculiar effects that cannot only be ascribed to COX-2 inhibition. In 
addition, it is worth noting that nimesulide, as already described above, is not only devoid of 
gatrolesivity, such as all COX-2 selective inhibitors, but it may protect by FANS-induced 
gastric ulcer and, highly important, in contrast to the other COX-2 inhibitors, nimesulide 
does not increase the risk of cardiovascular disease. There is evidence that no single 
mechanism is sufficient to account for all the anti-inflammatory activities of nimesulide and 
its molecular mechanisms are not well defined (Süleyman et al., 2008). An early work has 
demonstrated that the inhibitory effect of nimesulide on neutrophil function in vitro is 
mediated by adenosine (Capecchi et al., 1993); furthermore, several nimesulide cell 
functions have been attributed to the increased cAMP production as the consequence of  
phosphodiesterase IV (PDEIV) inhibition. Recently, it has been shown that nimesulide 
potentiates the anti-rheumatic profile of methotrexate in collagen–induced arthritis in mice. 
Authors have hypothesised that both drugs might share a common mechanism involving 
adenosine release or adenosine receptor activation on immune cells (Al-Abd et al., 2010). 
Thus, for these findings, nimesulide has piqued our interest and we tested the hypothesis of  
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the involvement of CD73/adenosine/A2A signalling pathway  in the anti-inflammatory effect 
of nimesulide in vivo (rat paw oedema) and in vitro (J774A.1 cell line). 
In the end, as already reported, physiological inflammation is a dynamic process, controlled 
by endogenous anti-inflammatory signals which are implicated in its development and 
resolution, adenosine is among them. It is well known that fibroblasts and extracellular 
matrix take an active part in the modulation of inflammation (Sorokin, 2010). There is 
evidence that fibroblasts, main producers of extracellular matrix components, can determine 
the nature and the duration of leukocyte infiltration (Buckley et al., 2001) and contribute to 
resolution of inflammation (Serhan et al., 2007). It has been shown that A2AAR activation 
beside anti-inflammatory effects promotes wound healing and extracellular matrix 
production (Montesinos et al., 1997), suggesting a role for adenosine signalling either in the 
acute phase of inflammation, mainly characterized by vascular events and leukocyte 
trafficking, or in the late phase, characterized by cell proliferation and tissue regeneration.  
Thus, we investigated whether and how the extracellular matrix was involved in the anti-
inflammatory effect mediated by A2A receptor activation. For this purpose, we evaluated  
changes in tissue FGF-2 (18 kDa), an important growth factor for fibroblasts that has been 
shown to facilitate not only tissue regeneration but also to dampen inflammation, following 
systemic administration of the A2A agonist, CGS 21680, in a model of acute inflammation, 
in vivo (rat paw oedema).   
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2. EXPERIMENTAL SECTION 
 
2.1 CD73 AND ACUTE INFLAMMATION 
2.1.1 MATERIALS AND METHODS 
2.1.1.1 Reagents  
APCP was purchased from Tocris Bioscience, (Bristol, UK); Malachite green phosphate 
assay kit was obtained from Sciencell, Research Laboratories (Carlsbad, USA); 
dithiothreitol (DTT), phenylmethylsulphonyl fluoride (PMSF) and leupeptine were 
purchased from ICN Pharmaceuticals (Italy). Bradford reagent was obtained from Bio-Rad 
Laboratories (Italy). enzyme-linked immunosorbent assay (ELISA) kits were purchased 
from R&D systems (Abingdon, UK). All salts and Giemsa reactive were purchased from 
Carlo Erba (Italy). Paraffin, Hematoxylin of Mayer solution and eosin 0.5% alcoholic 
solution were obtained from Kaltek (Padova, Italy). Polyclonal goat antibody to CD73 and 
monoclonal mouse antibody to -actin were purchased from Santa Cruz Biotechnology Inc. 
(Santa Cruz, CA). Anti-goat IgG  and anti-mouse IgG conjugated to horseradish peroxidase 
were obtained from Dako (Denmark). enhanced chemiluminescence (ECL) system was 
purchased from Amersham Pharmacia Biotech (Milan, Italy). All other reagents and 
compounds used were obtained from Sigma-Aldrich (Milan, Italy). 
2.1.1.2 Animals 
Male Wistar rats, body weight 220-260 g, were purchased from Harlan Nossan, (Milan, 
Italy). All animals were allowed to access to food and water ad libitum. The light cycle was 
automatically controlled and the room temperature was thermostatically regulated to 22 ± 1° 
C. Before the experiments, rats were housed and acclimatized under these conditions for 
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four days. All the in vivo procedures were performed according to the Italian and European 
regulations (DL/2014) on the protection of animals used for experimental and other 
scientific purposes and were approved by Italian Ministry of Health. Each experimental 
group consisted of five rats.  
2.1.1.3 Carrageenan-induced pleurisy in rats 
Male Wistar rats were slightly anaesthetized with 4% enflurane mixed with 0.5 L/min O2, 
0.5 L/min N2O; following a small skin incision at the level of the left sixth intercostal space 
and underlying muscle dissection, pleurisy was induced by injecting 200 μL of λ-
carrageenan solution 1% w/v (dissolved in distilled water) into the pleural cavity. Groups of 
rats were treated locally with the CD73 inhibitor (APCP, 400 μg/site), or with the respective 
vehicle (distilled water) immediately before carrageenan injection. The skin was then 
sutured and animals were returned to their cages and allowed to have food and water ad 
libitum. 4 and 72 hours following pleurisy induction, rats were sacrificed by CO2 inhalation, 
the chest was carefully opened, and exudate was harvested by washing each pleural cavity 
with 2 mL of sterile saline containing 10 U/mL heparin. Any exudate with blood 
contamination was discarded. The total volume was measured, next aliquots were taken to 
analyze the content in cells, cytokines, and AMPase activity. The leukocytes in the exudate 
were suspended in saline and counted with TC20™ Automated Cell Counter (Bio-Rad, 
Italy) after vital trypan blue staining and centrifugation (1200 rpm for 10 min); supernatants 
and cell pellets were frozen at -80°C, whereas differential cell count was determined in 
smears by May-Grunwald-Giemsa staining. 
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2.1.1.4 Western blotting analysis 
The inflammatory exudates recovered from the pleural cavity were washed twice in saline 
and the resulting suspensions were pelleted by centrifugation at 1200 rpm for 10 min at 4°C. 
The cell pellets were resuspended in 50 µL of ice-cold lysis buffer (200 mM HEPES, 400 
mM NaCl, 1 mM DTT, 1 % igepal, 20% glycerol, plus the protease inhibitor cocktail 
Roche) and maintained in constant agitation for 45 min at 4°C. Then the suspension was 
centrifuged at 14000 rpm for 10 min in a 4° C pre-cooled centrifuge and the supernatant 
(whole extract) was collected and stored at -80° C until analysis.  
Lung tissue was immediately transferred into a tube preloaded with one (6.35 mm) diameter 
zirconium oxide coated ceramic grinding sphere together with ice-cold lysis buffer (Tris-
HCl ,50 mM pH 7.5; NaCl, 150 mM; sodium orthovanadate, 1 mM; β glycerophosphate, 20 
mM; ethylenediaminetetraacetic acid (EDTA) , 2 mM; PMSF, 1 mM; leupeptin, 5 μg/mL; 
aprotinin, 5 μg/mL; pepstatin, 5 μg/mL) and put into a FastPrep®-24 homogenizer (MP 
Biomedicals, Santa Ana, California, USA) for lysis. The settings were 6.5 (speed) for 2x20 
s. In between the runs, the tube was cooled on ice for 5 min. The sample was then 
centrifuged for 15 min at 12000 rpm at 4° C and the supernatant (whole extract) was 
collected and stored at -80 °C until analysis. Protein concentration was determined by 
Bradford assay according to manufacturer’s instructions. Protein samples (35 µg) were 
mixed with 4X gel loading buffer (250 mM Tris, 8% sodium dodecyl sulphate (SDS), 40% 
glycerol, 20% 2-mercaptoethanol, 10 mg /mL of bromophenol blue) and heated for 5 min at 
95°C. Samples were then electrophoresed in an 8% discontinuous polyacrylamide gel and 
then transferred onto nitrocellulose membranes. Correct gel loading and transfer of proteins 
to the nitrocellulose membrane were confirmed by Ponceau staining. Afterwards, 
nitrocellulose membrane was blocked using a blocking solution containing 5% (w/v) non-fat 
dry milk in phosphate buffer saline (PBS) supplemented with  0.1% (v/v) tween 20, for 30 
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minutes at room temperature. It was then incubated overnight  at 4° C on a shaker with an 
anti CD73 polyclonal  goat antibody (1:200 dilution). The nitrocellulose membrane was 
washed three times for 10 minutes and then incubated for 2 h at room temperature with the 
secondary antibody anti-goat IgG (1:2000 dilution) conjugated with peroxidase. After three 
washes, protein bands were detected using the ECL detection kit and Image Quant 400 GE 
Healthcare software (GE Healthcare, Italy). Protein bands were quantified using Quantity 
One® software (Bio-Rad, Italy). Successively, to confirm the equal protein loading, 
membranes were stripped and incubated with anti β-actin monoclonal antibody (1:2000 
dilution) and subsequently with anti-mouse IgG conjugated to peroxidase (1:2000 dilution), 
both for 3 h at room temperature.  
2.1.1.5 Migration assay 
Chemotaxis was evaluated on cells obtained from pleural exudate collected 4 h after 
carrageenan injection in a 48-well modified Boyden chamber (AP48, Neuro Probe, USA). 
In brief, exudates were centrifugated at 1200 rpm for 10 min and cell pellets were 
suspended in saline and following trypan blue staining, were counted with TC20™ 
Automated Cell Counter (Bio-Rad, Italy). To evaluate chemotaxis, 50 μL of cell suspension 
(250 x 10
3 
cells in Roswell Park Memorial Institute (RPMI-1640) medium containing 0.1% 
bovine serum albumin (BSA) were placed on top of the polycarbonate filter (8 µm pore size, 
Neuro Probe, USA) whereas 25 μL of chemoattractant N-Formyl-L-methionyl-L-leucyl-L-
phenylalanine (fMLP, 1ng/mL in RPMI-1640 medium containing 0.1% BSA) were added to 
the lower wells. In another set of experiments, cells obtained from control group of rats 
were also pretreated with APCP 1 and 5 µM. Spontaneous migration was determined using 
RPMI-1640 medium (containing 0.1% BSA) alone. Each condition was set up in triplicate. 
Chambers were incubated for 1.30 h at 37°C in humidified air containing 5% CO2. 
Following incubation, the chamber was disassembled and the filter was carefully removed 
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and washed with sterile PBS. Cells that failed to migrate through the filter were wiped off 
the top surface of the filter. Migrated cells on the filter were fixed and stained with DAPI 
(Vector Laboratories, Burlingame, Ontario, Canada), and migration was quantified as the 
total pixel count of DAPI stained nuclei under the fluorescence microscope using Fiji 
software. Migration index was determined by dividing the number of cells migrated in the 
experimental condition by the number of cells migrated in the negative control cultures 
(medium only). 
2.1.1.6 Cytokine measurement 
TNF-α, IL-1, IL-6, MCP-1, IFN-γ, IL-17 levels  were evaluated in the exudate collected 4 
and 72 h after the induction of pleurisy. The assay was conducted by using ELISA kits 
according to the manufacturer's instructions.  
2.1.1.7 Morphological analysis 
Morphological analysis was performed on tissue samples from sham rats, APCP treated rats 
and control group of rats, to evaluate the effect of  CD73 inhibition on lung morphology 
following carrageenan-induced pleurisy. Lung biopsies were taken at 4 and 72 h after 
carrageenan injection and fixed for 1 week in formaldehyde solution (4% v/v, in distilled 
water) at room temperature, afterwards, tissues were processed and embedded in paraffin. 
Successively, in order to perform morphological analysis, tissue sections (7 μm thick) were 
deparaffinized with xylene and stained with haematoxylin and eosin. A minimum of 5 
sections per animal was analyzed by using a standard light microscope  (original 
magnification: x 20) and photographed by a Leica DFC320 video camera (Leica,Milan, 
Italy) connected to a Leica DM RB microscope by using the Leica Application Suite 
software V 4.1.0. 
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2.1.1.8 AMPase activity 
AMPase activity was assessed in cells and lungs collected from rats 4 and 72 h following 
pleurisy induction, as a measure of e-5’NT  activity, by colorimetric measurement of the Pi 
released following incubation with the substrate, as described by Nedeljkovic et al., (2006). 
In brief, on the day of analysis, protein extraction from inflamed cells and lungs were 
performed as described above. To initiate the enzymatic reaction, samples (50 µg of 
proteins) were incubated with 200 μL of medium containing MgCl2 (10 mM), NaCl (120 
mM), KCl (5 mM), glucose (60 mM), Tris-HCl (50 mM), pH 7.4. After 10 min, AMP (2 
mM) was added as substrate and samples kept at 37°C for 40 min. The reaction was then 
stopped by the addition of trichloroacetic acid (final concentration 5% w/v). Following 
sample centrifugation at 3000 rpm for 10 min, at 37°C, the release of Pi was measured using 
malachite green as a colorimetric reagent and KH2PO4 as standard (Chan et al., 1986). To 
have the net value of Pi produced following enzymatic reaction, aspecific Pi released in the 
absence of AMP in each sample was evaluated and the value obtained was subtracted from 
the value obtained following incubation with AMP. Protein concentration was measured by 
Bradford assay, using BSA as standard and results were expressed as Pi released (pmol/min/ 
µg protein). AMPase activity was also assessed in exudates collected from rats 4 and 72 h 
following pleurisy induction as a measure of soluble-5’NT activity by performing the same 
procedure described above. 
2.1.1.9 Statistical analysis 
All data are presented as means ± standard error  (S.E.); statistical analysis was performed 
on raw data by means of Student’s t-test for unpaired data or by one-way ANOVA followed 
by Bonferroni post-hoc test. A p value < 0.05 was considered statistically significant.
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2.1.2 RESULTS 
2.1.2.1 Leukocyte accumulation 
Local treatment with CD73 inhibitor, APCP (400 μg/site), significantly increased cell 
accumulation into the pleural cavity 4 h following carrageenan injection (Figure 15 A). 
There was no difference in the leukocyte number from exudates collected at 72 h after 
carrageenan injection from APCP-treated and control rats. Differential cell count of 
leukocytes migrated into the pleural cavity showed that PMNs dominated the early phase (4 
h) of the reaction and were replaced by monocytes (MCs) at 72 h (Figure 15 B; C).  
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Figure 15. Effect of APCP on leukocyte infiltration into the pleural cavity 4 and 72 h following 
carrageenan-induced rat pleurisy. A) Total leukocytes; B) and C) differential cell count. **p<0.01 vs ctrl. 
Student’s t-test (n=8).                                        
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2.1.2.2 Exudate formation 
Local treatment with APCP (400 μg/site) significantly increased the volume of exudate into 
the pleural cavity 4 h following carrageenan injection. There was no difference in exudate  
volume collected at 72 h after carrageenan injection from APCP-treated and control rats. 
(Figure 16). 
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Figure 16. Effect of APCP on exudate volume collected from the pleural cavity at 4 and 72 h after 
carrageenan injection. **p<0.01 vs ctrl. Student’s t-test (n=8). 
2.1.2.3 Cytokine measurement 
Following local treatment with APCP  there was a significant increase in TNF-α, IL-6, IL-
1 and MCP-1 levels evaluated in exudates collected  from the pleural cavity 4 hours 
following pleurisy induction  (Figure 17). In contrast, cytokines levels in exudate were not 
increased 72 h following carrageenan-induced pleurisy except for MCP-1 whose levels were 
still significantly increased by local treatment with APCP (400 μg/site) (Figure 18). 
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Figure 17. Effect of APCP on levels of TNF-α, IL-6, IL-1 and MCP-1 in exudates recovered from the 
pleural cavity 4 h following  carrageenan-induced rat pleurisy . *p< 0.05;***p<0.001 vs ctrl. Student’s t-
test (n=3).     
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Figure 18. Effect of APCP on levels of TNF-α, IFN-γ, IL-1, MCP-1, IL-17 in exudates recovered from 
the pleural cavity 72 h following carrageenan-induced rat pleurisy. *p< 0.05 vs ctrl. Student’s t-test (n=3). 
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2.1.2.4 Western blotting analysis 
Western blotting analysis performed on cells recruited into the pleural cavity at 4 after 
carrageenan injection revealed a reduced CD73 expression from APCP treated group of rats 
(Figure 19 A). In contrast, there was no difference on cells from exudates collected 72 h 
following pleurisy induction from APCP-treated and control rats (Figure 19 B).  
 
 
 
 
 
 
 
 
Figure 19. Detection of CD73 by western blotting analysis on cells collected from pleural exudates 4 h 
(A) and 72 h (B)  following carrageenan-induced rat pleurisy and C) densitometric analysis (O.D. optical 
density). *p< 0.05 vs ctrl. Student’s t-test (n=5). 
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Western blotting analysis performed on lungs collected 4 and 72 h following carrageenan-
induced pleurisy from APCP treated group of rats and ctrl did not show any significant 
difference (Figure 20).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Detection of CD73 by western blotting on lung tissues collected 4 h (A) and 72 h (B)  following 
carrageenan-induced rat pleurisy and C) densitometric analysis (O.D. optical density).  
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2.1.2.5 AMPase activity 
Local treatment with APCP significantly reduced AMPase activity in exudate, cell lysate,  
and lung homogenates 4 h following carrageenan injection, demonstrating CD73 specific 
inhibition, whereas at 72 h AMPase activity was not different from control values, in any of 
the tissues considered (Figure 21). 
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Figure 21. AMPase activity in cells (A), lungs (B), exudates (C) collected 4 and 72 h following 
carrageenan-induced pleurisy. *p<0.05; **p<0.01; p<0.001 vs ctrl. Bonferroni's Multiple Comparison Test 
(n=5). 
2.1.2.6 Chemotaxis assay  
Cells obtained from exudates collected from APCP treated group of rats 4 h after 
carrageenan injection showed increased ability to migrate in vitro either in presence (Figure 
22, A) or in absence (Figure 22 B) of a chemotactic stimulus (fMLP), compared to cells 
from control groups (Figure 22 C and D). The ability to migrate of cells obtained from 
exudates collected from control group of rats 4 h after carrageenan injection was strongly 
increased following in vitro treatment with APCP (1 and 5 µM; Figure 22, E and F) in a 
concentration-dependent manner.   
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Figure 22. Effect of APCP on chemotaxis of leukocytes collected 4 h after carrageenan injection. 
Representative immunofluorescence showing DAPI-stained nuclei from A) APCP treated group + fMLP; B) 
APCP treated group – fMLP; C) CTRL group + fMLP; D) CTRL group – fMLP; E) CTRL group + fMLP + 
APCP 1 µM in vitro; F) CTRL group + fMLP + APCP 5 µM in vitro. Original magnification: x10. G) 
migration index. *** and 
§§§ 
p<0.001 vs ctrl. Bonferroni's Multiple Comparison Test (n=8). 
2.1.2.7 Morphological analysis 
Morphological analysis of lung sections of carrageenan-treated rats showed cell infiltration 
of the bronchial and perivascular space as well as lung injury  (Figure 23 B, C, D, E).  No 
histological alterations were found in sham-rats (Figure 23 A). Local treatment with APCP  
increased both lung cells infiltration and lung injury 4 h following carrageenan-induced 
pleurisy (Figure 23 C). No histological alterations between ctrl and APCP treated group of 
rats were found at 72 h (Figure 23 D and E).  
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Figure 23. Effect of APCP on lung injury 4 and 72 h following carrageenan-induced pleurisy. 
Representative morphological analysis of hematoxylin and eosin (H&E)-stained lung sections, from A)sham 
rats; B) ctrl group at 4 h; C)APCP group at 4 h; D)ctrl group at 72 h; E) APCP group at 72 h. Original 
magnification: x20. n=5. 
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2.2 CD73/ADENOSINE/A2AAR SIGNALLING PATHWAY 
AND NIMESULIDE ANTI-INFLAMMATORY EFFECT 
2.2.1 MATERIALS AND METHODS 
2.2.1.1 Reagents  
Nimesulide, dymethysulfoxide (DMSO), AMP, λ-carrageenan, celecoxib, LPS from 
Escherichia Coli (serotype 011:B4) and MTT were purchased from Sigma-Aldrich (Milan, 
Italy); CGS 21680, ZM 241385, APCP were obtained from TOCRIS Bioscience (Bristol, 
UK); PGE2 , enzymatic immune assay (EIA) assay kit was purchased from Cayman 
(Tallinn, Estonia); Malachite Green kit was purchased from ScienCell, Research 
Laboratories (Carlsbad, USA). Polyclonal goat antibody to CD73 and monoclonal mouse 
antibody to -actin were obtained from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). 
Antibody for COX-2 was purchased from BD Biosciences (San Jose, USA). Anti-goat IgG  
and anti-mouse IgG conjugated to horseradish peroxidase were obtained from Dako 
(Denmark). ECL system was obtained from Amersham Pharmacia Biotech (Milan, Italy). 
All salts were purchased from Carlo Erba (Italy). All reagents for cell culture were obtained 
from Sigma-Aldrich  (Milan, Italy), Amersham Biosciences Inc. (UK), Bio-Rad 
Laboratories (USA) and Microtech (Naples, Italy). All other salts and reagents were 
purchased from Carlo Erba (Milan, Italy).  
2.2.1.2 In vivo experiments 
2.2.1.3 Animals 
Male Wistar rats, body weight 200–250 g, were purchased from Harlan Nossan, (Milan, 
Italy). Animals were kept under standard conditions with food and water ad libitum and 
maintained in a 12 h/12 h light/dark cycle at 22 ± 1° C. Before the experiments, rats were 
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housed and acclimatized under these conditions for four days. All the in vivo procedures 
were performed according to the Italian and European regulations (DL/2014) on the 
protection of animals used for experimental and other scientific purposes and were approved 
by Italian Ministry of Health.  
2.2.1.4 Carrageenan-induced paw oedema 
Rats, slightly anesthetized with 4% enflurane mixed with 0.5 L/min O2, 0.5 L/min N2O, 
received in the left hind paw a subplantar injection of 100 μL of λ-carrageenan (suspension 
1% w/v). Paw volume was measured at the time zero and each hour for 6 h by a 
hydropletismometer (Ugo Basile, Comerio, VA, Italy). 
2.2.1.5 Drug treatments 
Rats were assigned to groups of 5 and treated intraperitoneally (i.p.), just before oedema 
induction, with the A2A agonist, CGS 21680 (2 mg/kg), or with the A2A antagonist, ZM 
241385 (3 mg/kg), given alone or in combination. In another series of experiments, animals 
were treated with nimesulide (5 mg/kg i.p) given alone or co-administered with ZM 241385 
(3 mg/kg i.p.), just before carrageenan injection. Control groups received the vehicle, 
DMSO (0.5 ml/kg). The effect of CD73 inhibitor, APCP, injected into the rat paw (400 
μg/paw) 1 h following carrageenan injection, was also evaluated in both controls and 
nimesulide-treated animals. Animals were then sacrificed and inflamed tissues were excised 
and immediately frozen in liquid nitrogen and stored until further analysis.  
2.2.1.6 Blood collection and plasma preparation 
In some experiments, blood was withdrawn 4 h following oedema induction by cardiac 
puncture and anticoagulated with trisodium citrate (3.8 % w/v). Plasma was then obtained 
by centrifugation at 3000 rpm for 15 min.  
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2.2.1.7 Enzymatic assay in rat inflamed tissues and plasma 
AMP hydrolysis was evaluated in samples of inflamed tissues and of plasma collected from 
rats 4 h following oedema induction, as a measure of e-5’NT  and soluble-5NT activity, by 
colorimetric measurement of the Pi released following incubation with the substrate, as 
described by Nedeljkovic et al.,(2006). Briefly, on the day of analysis, inflamed tissues 
were homogenized using liquid nitrogen in the following lysis buffer: Tris-HCl (50 mM) pH 
7.5; NaCl (150 mM); sodium orthovanadate (1 mM); β-glycerophosphate (20 mM); EDTA 
(2 mM); PMSF (1 mM); leupeptin (5 μg/ml); aprotinin (5 μg/ml); pepstatin (5 μg/ml). 
Protein concentration was determined by the Bio-Rad protein assay kit (Bio-Rad 
Laboratories, Milan, Italy). To initiate the enzymatic reaction, samples of tissue 
homogenates or plasma (50 μg of proteins) were incubated with 200 μL of medium 
containing MgCl2 (10 mM), NaCl (120 mM), KCl (5 mM), glucose (60 mM), Tris-HCl (50 
mM), pH 7.4. After 10 min, AMP (2 mM) was added as substrate and samples kept at 37°C 
for 40 min. The reaction was then stopped by the addition of trichloroacetic acid (TCA, final 
concentration 5% w/v). Following sample centrifugation at 3000 rpm for 10 min, at 37°C, 
Pi released was quantified using malachite green as a colorimetric reagent and KH2PO4 as 
standard (Chan et al., 1986). To have the net value of Pi produced following enzymatic 
reaction, aspecific Pi released in the absence of AMP in each sample was evaluated and the 
value obtained was subtracted from the value obtained following incubation with AMP. All 
samples were run in triplicate; results were expressed as Pi released (pmol/min/μg protein). 
2.2.1.8 Prostaglandin E2 assay 
Levels of PGE2 were assayed in plasma obtained from inflamed rats 4 h following 
carrageenan paw oedema by EIA kit according to the manufacturer’s instructions and 
expressed as pg/ml. 
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2.2.1.9 Western blotting analysis 
From nimesulide-treated rats and control animals, at different times following oedema 
induction, inflamed paws were excised and the soft tissue was removed, frozen in liquid 
nitrogen and stored. Tissue samples were then defrosted, weighed and homogenized. Protein 
extraction was performed as described previously and the protein concentration was 
measured by the Bradford assay using BSA as standard. Denaturated protein samples (35 
𝜇g) were subjected to electrophoresis on an SDS 8% polyacrylamide gel and transferred 
onto a nitrocellulose transfer membrane (Protran, Schleicher & Schuell, Germany). The 
membranes were saturated by incubation with non-fat dry milk (5% w/v) in PBS 
supplemented with 0.1% (v/v) Tween 20 for 1 h at room temperature and then incubated 
with a goat polyclonal anti-CD73 antibody (1:200 dilution), overnight at 4° C. Successively, 
membranes were washed and then incubated with the secondary antibody conjugated with 
horseradish peroxidase (HRP), anti-goat IgG-HRP (1:2000 dilution), for 2 h at room 
temperature. Protein bands were detected using the ECL detection kit and Image Quant 400 
GE Healthcare software (GE Healthcare, Italy). Protein bands were quantified using 
Quantity One® software (Bio-Rad, Italy). Successively, to confirm the equal protein 
loading, membranes were stripped and incubated with anti β-actin monoclonal antibody 
(1:2000 dilution) and subsequently with anti-mouse IgG conjugated to peroxidase (1:2000 
dilution), both for 3 h at room temperature. 
2.2.1.10 In vitro experiments 
2.2.1.11 Cell culture 
The murine monocyte/macrophage cell line J774A.1 (American Type Culture Collection, 
Rockville, MD) was grown at 37°C, in humidified 5% CO2/95% air in Dulbecco's modified 
Eagle's medium (DMEM) supplemented with 10 % foetal bovine serum (FBS), 25 mM 
HEPES, 100 U/ml penicillin, 100 mg/ml streptomycin and 1% sodium pyruvate. The cells 
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were maintained in 10 cm
2
 dishes and for experiments were plated in 6, 24 or 96 culture 
wells at a density of 2.5×10
5
 cells/ml/well for 18 h.  
2.2.1.12 Cell treatment 
Non-adherent cells were removed by washing with sterile PBS and, immediately before the 
experiments, the culture medium was replaced by fresh medium. Cells were pre-incubated 
with the following compounds: the A2A agonist, CGS 21680 (1 μM) alone or in combination 
with the ZM 241385 (10 μM); nimesulide (100 μM) alone or in combination with the A2A 
antagonist, ZM 241385 (10 μM), or with the CD73 inhibitor, APCP (5 μM), celecoxib (10 
μM) alone or in combination with APCP (5 μM) or with ZM 241385 (10 μM); PGE2, (30–
300 µM). Drug concentrations to be used throughout the whole study were established 
following preliminary experiments. All incubations were performed 1 h before cell 
activation with LPS from Escherichia Coli  (1 g/mL) except for ZM 241385 that in some 
experiments was added 6 hours following cell incubation with nimesulide or with celecoxib. 
Controls were performed by cell incubation with DMSO (final concentration 0.05 %) that 
was the vehicle for all compounds, apart from APCP that was dissolved in the cell medium. 
Following LPS activation, cells were then maintained for 24 h in a humidified incubator at 
37 °C under 5% CO2 atmosphere.  
2.2.1.13 Cell viability assay 
To exclude that all stimuli used induced cell death, cell viability was determined by 
evaluating total mitochondrial activity using the MTT assay. Briefly, 25 μL of MTT (5 
mg/ml in PBS) solution was added to each well incubated for 3 h. Thereafter, the cells were 
lysed and the dark blue crystals solubilized with 100 μL of a solution containing 50% (v/v) 
N,N-dimethylformamide and 20% (w/v) SDS with an adjusted pH of 4.5. The optical 
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density was read at 570 nm in a microplate reader and the results were expressed as a 
percentage (%) of cell viability. 
2.2.1.14 Nitrite assay 
J774A.1 cells were cultured and treated as described above. The nitrite production was 
measured as described by Green et al., (1982). Briefly, 100 µl of the culture medium 24 
hours following challenge with LPS was mixed with an equal volume of Griess reagent (1% 
sulphanilamide and 0.1% naphthyl ethylenediamine in 5% phosphoric acid) and incubated 
at room temperature for 10 min. The absorbance at 540 nm was recorded using a microplate 
reader. The amount of nitrite (as μmol/L) was calculated by extrapolation from a sodium 
nitrite standard curve.  
2.2.1.15 Prostaglandin E2 assay 
Levels of PGE2 were assayed in the cell culture medium by EIA kit according to the 
manufacturer’s instructions and expressed as pg/ml. 
2.2.1.16 Enzymatic assay  
AMPase activity was evaluated in 24 well plates containing J774A.1 macrophage cell line 
(2.5×10
3 
cells/well) plated for 18 h, treated as described above and incubated with or 
without LPS for 24 h. Afterwards, cells were washed three times with incubation medium 
without AMP. The enzymatic reaction was then started by the addition of 200 μL of 
incubation medium as described previously, without Tris-HCl, and with some differences: 
MgCl2 (2 mM); glucose (10 mM) and HEPES (20 mM), pH 7.4. After 10 min of incubation, 
the reaction was stopped by collecting an aliquot of the incubation medium and transferring 
it into Eppendorf tubes containing TCA (final concentration, 5 % w/v), previously placed on 
ice. Controls to determine non-enzymatic Pi release were performed by incubating the cells 
in the absence of the substrate, or the substrate in the absence of the cells. To determine 
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specificity, experiments were also performed in cells in the presence of the CD73 inhibitor, 
APCP. All samples were run in triplicate. The release of Pi was measured by the malachite 
green method, using KH2PO4 as a Pi standard, as described above. To have the net value of 
Pi produced following enzymatic reaction, Pi released by AMP into the assay medium 
without cells was subtracted from the total Pi released by cells during incubation with AMP, 
and expressed as pmol/min. 
2.2.1.17 Ultra-Performance Liquid Chromatography (UPLC)   
In another series of experiments, CD73 activity on J774A.1 macrophage cell line treated as 
described above was also assessed by quantifying the conversion of ε-AMP, a bioactive, 
fluorescent analog of AMP (BIOLOG, Bremen, Germany) to ε-adenosine (Jamal et al., 
1988), using Ultra-Performance Liquid Chromatography (UPLC) analysis. The product ε-
adenosine is neither a substrate for nor an inhibitor of adenosine deaminase, which catalyzes 
the irreversible deamination of adenosine and deoxyadenosine to inosine and deoxyinosine, 
respectively, decreasing adenosine levels (Jamal et al., 1988). Briefly, cells were washed 
three times with Hank’s Balanced Salt Solution (HBSS) (GibcoTM, Thermo Fisher 
Scientific, Waltham, MA, USA) without ε-AMP. Afterward, the cells were incubated with 
ε-AMP (50 μM) in HBSS for 10 minutes at 37 °C. To determine specificity, a similar 
analysis was performed in cells untreated in the presence of the CD73 inhibitor, APCP (50 
μM). To stop the reaction an aliquot of 60 μl of the incubation medium was transferred into 
an Eppendorf tube on ice and centrifuged at 4 °C for 2.5 min at 550 x g. Aliquots of 40 μl 
were applied to an ACQUITY UPLC® H-Class Bio (WATERS Corp. Milford, MA, USA) 
and nucleotides and nucleosides were separated by running a linear gradient of buffer A 
(150 mM KCl/150 mM KH2PO4 at pH 6) and buffer B (15% (v/v) solution of acetonitrile in 
buffer A) with a flow profile of 0,294 ml/min (0-0.54 min. 100% A; 0.54-1.24 min. 97% A 
and 3% B; 1.24-4.17 min. 91% A and 9% B; 4.17-7.45 min. 50% A and 50% B; 7.45-8.37 
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min. 50% A and 50% B; 8.37-8.45 min. 100% A) using a high pressure gradient mixing 
device. The performance was done on an Acquity UPLCTM BEH C18 column (2.1×150 
mm, 1.7 μm; WATERS Corp. Milford, MA, USA). The analyte ε-adenosine was detected at 
254 nm by using Waters Multi λ Fluorescence detector 2475 (λEM=410 nm,  λEx=280 nm) 
and its concentration was calculated with reference to standards of known concentration (ε-
adenosine; BIOLOG, Bremen, Germany) and expressed as pmol/min. UPLC analysis was 
also used for the simultaneous quantification of ATP, nicotine amide dinucleotide (NAD), 
ADP, AMP, adenosine, inosine, hypoxanthine, xanthine produced by J774A.1. The 
EMPOWER 3 software (WATERS Corp. Milford, MA, USA) was used for data analysis. 
These experiments were performed at Professor Jürgen Schrader’s laboratory, Department 
of  Molecular Cardiology, “Heinrich Heine University”, Düsseldorf, Germany.  
2.2.1.18 Transfection and real time PCR 
For silencing of CD73 mRNA by small interfering RNA (siRNA), J774A.1 cells were 
double shot transfected using HiPerfect (Qiagen, Germany) according to manufacturer’s 
instructions, with a combination of two siRNAs (Sigma-Aldrich, Milan, Italy) specific for 
the CD73 or one siRNA (Sigma-Aldrich, Milan, Italy) specific for the green fluorescent 
protein (GFP). 
The sequences CD73 targeted by the siRNAs were: 5-CAUUGCAGCCUGAAGUAGA-3 
and 5-GACAUUUGACCUCGUCCAA-3. The GFP sequence targeted by the siRNA was 5-
CGGCAAGCUGACCCUGAAGUUCAU-3 and analyzed for mRNA expression levels after 
96 hours. Total RNA was isolated from J774A.1 cells with TRI Reagent® (Sigma-Aldrich, 
Milan, Italy) and analyzed spectroscopically. One microgram of RNA was retro-transcribed 
using Prime Script RT reagent Kit with gDNA eraser (Takara, Otsu, Japan) and amplified 
with specific primers described below. For CD73 mRNA fw: 5-
GCGTGCATCGCTATGGCCAGTCC 3 and rv: 5- CCACCGTTGGCCAGATAGCTTGG-
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3 and fw: 5-AAAACCAACCCGGTGAGCTCCCTC-3 and rv: 5-
CTCAGGCTCCCTCTCCGGAATCG-3 for 18s, all primers were purchased from IDT 
(IDT, Germany). PCR amplification was carried out as by means of SYBR Premix Ex Taq 
(Takara, Otsu, Japan) according to manual instruction. PCR amplification of 18s rRNA was 
used as the normalizer. Real-time PCR assays were performed using the Rotorgene RG-
3000A cycle system (Qiagen, Germany). These experiments were performed in 
collaboration with Drs. Astrid Parenti, Sara Paccosi, Andrea Lapucci (Department of Health 
Sciences, Clinical Pharmacology and Oncology Section; “University of Florence”, Florence, 
Italy). 
2.2.1.19 Fluorescence-activated cell sorting (FACS) analysis 
The expression of the protein CD73 in J774A.1 silenced for 96 hours and in untreated 
control was evaluated by flow cytometry platform FACS CANTO II (BD, Franklin Lakes, 
NJ, USA) after the determination of nitrite release. Monoclonal antibody APC anti-mouse 
CD73 (clone: TY/11.8; Biolegend, San Diego, CA, USA) and the isotype-identical antibody 
as control were used for this purpose. Dead cells were excluded by 7-ADD (Sigma-Aldrich, 
St. Louis, MO, USA). Results were analyzed with FCS Express 5.0 software (De Novo, 
Glendale, CA, USA). These experiments were performed in collaboration with Drs. Astrid 
Parenti, Sara Paccosi, Andrea Lapucci, (Department of Health Sciences, Clinical 
Pharmacology and Oncology Section, “ University of Florence”, Florence, Italy).  In another 
set of experiments, J774 macrophages were cultured in 24-well plates and treated as 
described above. After 24 hours, the cells were harvested, resuspended in MACS buffer 
(BSA 0.5%, EDTA 5 mM in PBS) and pre-incubated with FcR Blocking Reagent (Miltenyi 
Biotech, Auburn, CA, USA) for 10 min at 4 °C. Then the cells were stained with the 
following antibodies: CD11b APC-conjugated antibody (clone: M1/70.15.11.5; isotype: rat 
IgG2b; 1:100 dilution; Miltenyi Biotech, Auburn, CA, USA) and with Mouse 5'-
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Nucleotidase/CD73 PE-conjugated Antibody (clone:496406; isotype: Rat IgG2a; 1:10 
dilution; R&D systems, Abingdon, UK) for 20 min at 4 °C in dark.  After two washes, cells 
were analyzed on Fluorescence-activated cell sorting analysis (FACS). J774A.1 were also 
DAPI-stained to exclude dead cells. Subsequently, percentage of cells expressing CD73 was 
determined by FACS after gating CD11b+ living cells. FACS analysis was carried out on an 
FACS Calibur FACS Canto, or LSR II (BD Biosciences, Heidelberg, Germany). Ten 
thousand cells were analyzed in each sample.  Data analysis was performed using FlowJo 
7.6.1 software (Tree Star, Inc., Ashland, OR, USA) and results were expressed as a 
percentage of cells positive for CD73. These experiments were performed at Professor 
Jürgen Schrader’s laboratory, Department of  Molecular Cardiology, “Heinrich Heine 
University”, Düsseldorf, Germany. 
2.2.1.20 Western blotting analysis 
Cells treated as reported previously were washed three times with ice-cold PBS and were 
removed from the culture dish. The resulting suspension was pelleted by centrifugation at 
1200 rpm for 5 min at 4°C. The cell pellet was resuspended in 50 µL of ice-cold lysis buffer 
(200 mM HEPES, 400 mM NaCl, 1 mM dithiothreitol DTT, 1 % igepal, 20% glycerol, 
along with the protease inhibitor cocktail Roche) and maintained in constant agitation for 45 
min at 4°C. Then the suspension was centrifuged at 14000 rpm for 10 min in a 4° C pre-
cooled centrifuge and the supernatant was collected and stored at -80 °C until analysis. 
Immunoblotting analysis of COX-2 protein was performed on whole cell extracts. 
Denatured proteins (35 µg) were electrophoresed in an 8% discontinuous polyacrylamide 
gel and then transferred onto nitrocellulose membranes. Afterward, nitrocellulose membrane 
was blocked using non-fat dry milk (5% w/v) in PBS supplemented with 0.1% (v/v) Tween 
20  for 30 minutes at room temperature and then incubated overnight  at 4° C on a shaker 
with an anti COX-2  mouse antibody (1:1000 dilution). The nitrocellulose membrane was 
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washed five times for 30 minutes and then incubated with the secondary antibody anti-
mouse IgG (1:2000 dilution), conjugated with peroxidase for 2 h at room temperature. After 
three washes, the proteins bands were detected using the enhanced chemiluminescence 
method and analyzed with Quantity One program as described by the manufacturer. 
Successively, to confirm the equal protein loading, membranes were stripped and incubated 
with anti β-actin monoclonal antibody (1:2000) and subsequently with anti-mouse IgG 
conjugated ed to peroxidase (1:2000), both for 3 h at room temperature. 
2.2.1.21 Statistical analysis 
All results were expressed as mean ± standard error (S.E.); each in vitro experiment was run 
in triplicate. Data were analyzed by one way ANOVA followed by Bonferroni’s test for 
multiple comparisons or by Dunnett’s test, as appropriate. Two ways ANOVA was also 
utilized when appropriate. A value of p< 0.05 was taken as statically significant.
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2.2.2 RESULTS  
2.2.2.1 In vivo experiments 
2.2.2.2 Carrageenan–induced oedema 
Treatment of rats with the selective A2A agonist, CGS 21680 (2 mg/kg i.p.), significantly 
inhibited oedema formation monitored over a period of 6 hours (Figure 24 A) and this effect 
was reversed by co-administration with the A2A antagonist, ZM 241385 (3 mg/kg i.p.). In 
contrast treatment with ZM 241385 alone did not modify oedema development (Figure 24 
A). In animals receiving nimesulide (5 mg/kg i.p.), oedema formation was significantly 
reduced and this effect was partially reversed by treatment with ZM 241385 (Figure 24 B).  
 
 
 
  
         
           
 
 
 
Figure 24. Effect of drug treatments on carrageenan-induced rat paw oedema. *p< 0.05 , ** p< 0.01, *** 
p < 0.001 vs. control. Two ways ANOVA followed by Bonferroni’s test (n=10). 
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Figure 24. Effect of drug treatments on carrageenan-induced rat paw oedema. *p< 0.05 , ** p< 0.01, 
***p< 0.001 vs. control.Two ways ANOVA followed by Bonferroni’s test (n=10). 
2.2.2.3 Prostaglandin E2 assay 
The anti-inflammatory effect of nimesulide was associated with a significant reduction of 
plasma PGE2 levels, evaluated 4 hours following oedema induction, consistent with COX-2 
inhibition; however, PGE2 plasma levels were only slightly, but not significantly, reduced 
by treatment with CGS 21680 (Figure 25). 
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Figure 25. Effect of  nimesulide and CGS 21680 on PGE2 plasma levels 4 hours following oedema 
induction. *** p < 0.001 vs. control. Bonferroni’s test for multiple comparisons (n=5). 
2.2.2.4 AMPase activity in inflamed tissues and plasma 
The anti-inflammatory effect of nimesulide was accompanied by change in AMPase activity 
in inflamed tissues and plasma evaluated 4 h following oedema induction, that represented 
the inflammatory peaking point. In paws obtained from nimesulide-treated rats, AMP 
hydrolysis was significantly increased compared to the hydrolysis measured in paws from 
control animals (Figure 26 A). This increased AMPase activity was of functional 
significance since local injection of the CD73 inhibitor, APCP (400 μg/paw), did not affect 
oedema development (Figure 26 B) but reverted nimesulide effect (Figure 26 C). AMP 
hydrolysis was also significantly increased in plasma obtained from animals treated with 
nimesulide (Figure 26 D).  
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Figure 26. Effect of systemic treatment with nimesulide on AMPase activity in paws (A) and in plasma 
(D) 4 hours following oedema induction. ** p< 0.01 vs. control; one way ANOVA followed by Dunnett’s 
test (n=8); and effect of CD73 inhibitor (APCP, 400 µg/paw) on rat paw oedema and nimesulide anti-
inflammatory effect (B, C). *p < 0.05, ** p< 0.01 vs. control. Two ways ANOVA followed by Bonferroni’s 
test (n = 5). 
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2.2.2.5 Western blotting analysis 
CD73 expression was evaluated by Western blotting analysis on inflamed tissues obtained 
each hour following oedema induction. There was no difference in the expression of CD73 
in inflamed paws obtained from control (Figure 27A) and nimesulide (Figure 27 B) treated 
rats.   
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Figure 27. Detection of CD73 by western blotting analysis in inflamed  paws  from control  (A) and 
nimesulide (B) treated rats each hour following oedema induction and C) densitometric analysis (O.D. 
optical density). (n = 3).  
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2.2.2.6 In vitro experiments 
2.2.2.7 Cell viability assay 
Cell viability evaluated 24 hours following incubation with MTT was not modified by 
treatments described (Figure 28).  
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Figure 28. Effect of LPS, vehicle (DMSO), CGS 21680, nimesulide, celecoxib, ZM 241385 and APCP on 
cell viability evaluated 24 h following incubation with MTT in J774A.1.  
2.2.2.8 Nitrite production  
Production of nitrite by un-stimulated J774 cells was undetectable (< 0.8 μM). Stimulation 
with LPS caused a substantial release of nitrite (26.0 ± 0.9 μM, n=5) that was significantly 
reduced by the adenosine A2A receptor agonist, CGS 21680 (1μM). The inhibitory effect of 
CGS 21680 (1μM) was reverted by cell co-treatment with the A2A antagonist, ZM 241385 
(10 μM; Figure 29 A). Similarly, nimesulide (100 μM) inhibited nitrite production from 
LPS–activated J774 and its effect was reverted by the A2A antagonist, ZM 241385 (10 μM), 
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6 hours following nimesulide treatment (Figure 29 B). ZM 2141385 did not have any effect 
when added to J774 together with nimesulide (data not shown). The inhibitory effect of 
nimesulide on nitrite production from LPS–activated J774 was also fully reverted by the 
CD73 inhibitor, APCP (5 μM, Figure 29 C). However, the inhibitory effect of celecoxib (10 
μM) on nitrite accumulation from LPS-activated J774 was neither affected by ZM 241385 
nor by APCP (Figure 29 B and C). Exogenously added PGE2 inhibited, in a concentration- 
related manner, nitrite production from LPS–activated J774 cells without affecting nitrite 
production from not stimulated cells (Figure 29 D). 
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Figure 29. Effect of treatments on nitrite production from LPS-activated J774A.1 macrophages. A) *** 
p< 0.001 vs. vehicle and 
§§§
 p<0.001 vs. CGS 21680; B) ***p <0.001 vs. vehicle and  §§§ p <0.001 vs. 
nimesulide; C) 
§§§
 p <0.001 vs. nimesulide and *** p<0.001 vs. vehicle; D) ***p <0.001 vs. vehicle. 
Bonferroni's Multiple Comparison Test (n = 5–8). 
2.2.2.9 Ecto-5’ nucleotidase (e-5’NT)/CD73 activity  
LPS–activated J774 (250 x 103/well) showed reduced AMPase activity evaluated as Pi 
(pmol/min) accumulation following incubation with AMP (2 mM). Nimesulide (100 μM) 
increased Pi accumulation in both non-activated and LPS-activated cells. (Figure 30 A). The 
specificity of nimesulide effect was proved by evidence that it was blocked by CD73 
inhibitor, APCP (5 μM). APCP also significantly reduced Pi accumulation from naïve cells 
(from 17.67 ± 1.4 μM, n=9 to 3.7 ± 1.8 μM, n= 3; p <0.001). AMP hydrolysis was not 
affected when J774 were incubated with celecoxib (Figure 30 B). AMPase activity was also 
evaluated as etheno adenosine-accumulation using ε-AMP as substrate by UPLC analysis. 
Similar to data described above, nimesulide (100 μM) increased CD73 activity by non-
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activated and LPS-activated cells (250 x 10
3
/well) while it was unaffected by celecoxib (10 
μM) (Figure 30 C). 
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Figure 30. Ecto-5’nucleotidase/CD73 activity in J774 evaluated as Pi accumulation (A,B) and as etheno 
adenosine-accumulation (C). A)** p <0.05 and *** p <0.001 vs.– LPS/vehicle; §§§ p <0.001 vs. + 
LPS/vehicle; B) *** p < 0.001 vs. vehicle and §§§ p <0.001 vs. nimesulide; C) * p <0.05 vs. - LPS/vehicle; § p 
<0.05 vs. + LPS/vehicle. Bonferroni's Multiple Comparison Test (n = 6).  
2.2.2.10 Nucleotides and nucleosides production by J774A.1 
It is well known that nucleotides and nucleosides are  involved in the inflammatory process. 
UPLC analysis showed that there was no difference in ATP, NAD, ADP, inosine, 
hypoxanthine production by J774A.1 among different treatments. 
Consistent with an increased CD73 activity, following incubation with nimesulide we 
observed a slight, not significant, reduction  in AMP production and a significant increase in 
adenosine production by both non-stimulated and LPS-stimulated cells. 
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Figure 31. Production of A) ATP; B) NAD; C) ADP; D) AMP; E) Adenosine; F) Inosine; G) 
Hypoxanthine by J774A.1. *** p < 0.001 vs. - LPS/vehicle and 
§§§
 p <0.001 vs. + LPS/vehicle. Bonferroni's 
Multiple Comparison Test (n = 6).   
2.2.2.11 PGE2 assay 
There was a significant increase in PGE2 production following J774 activation with LPS 
that was almost completely inhibited by nimesulide (100 μM). Either ZM 241385 (10 μM) 
and APCP (5 μM) increased PGE2 levels of nimesulide-treated cells above control value 
(Figure 32). Treatment of cells with CGS 21680 (1 μM) did not significantly modify PGE2 
production from LPS activated J774 (662.3 ± 53.28 pg/ml vs. 770.8 ± 42.56 pg/ml; 
Bonferroni's Multiple Comparison Test, n= 6). 
 
 
 
 
 
 
 
G 
  
107 
 
0
500
1000
1500
- LPS
+LPS
n
im
e
s
u
lid
e
***
§§§
v
e
h
ic
le
n
im
esu
lid
e +
 A
P
C
P
**
§§§
n
im
e
su
lid
e
 +
 Z
M
 2
4
1
3
8
5
P
G
E
2
(p
g
/m
l)
 
 
2.2.2.12 Western blotting analysis  
Western blotting analysis performed on J774A.1 cell line showed that following activation 
with LPS there was a significant increase of  COX-2 expression that was not affected by 
nimesulide (Figure 33). 
 
 
 
                            vehicle nimesulide  vehicle nimesulide 
+LPS -LPS -LPS 
A 
-actin 
COX-2 
Figure 32. PGE2 accumulation in the culture medium. ** p<0.01 and *** p<0.001 vs. vehicle; 
§§§
 p <0.001 
vs. nimesulide. Bonferroni's Multiple Comparison Test (n = 6). 
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Figure 33. Detection of COX-2 enzyme by western blotting analysis (A) in J774A.1and B) densitometric 
analysis (O.D. optical density). ***p<0.001 vs cells –LPS. Dunnett's Multiple Comparison Test (n = 6). 
 
2.2.2.13 Fluorescence-activated cell sorting (FACS) analysis 
LPS significantly increased  e-5’NT/CD73 expression on J774A.1 (87.1 ± 3 % CD73+ cells; 
***
p<0.001 vs. cells;  Dunnett's Multiple Comparison Test (n=5); Figure 34C). Neither 
nimesulide nor celecoxib modified e-5’NT/CD73 expression on macrophage cell line 
J774A.1.  
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Figure 34. Representative plots illustrating the gating used to identify J774A.1 defined as CD11b+ cells 
(A) and viable cells defined on the basis of a negative DAPI-staining (B) by flow cytometry. C) 
histograms representing flow cytometric analysis of the surface expression of CD73 on J774A.1. 
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2.2.2.14 SiRNA CD73 silencing 
After siRNA treatment, CD73 transcripts were reduced by 69 ± 12 % (n=3) as revealed by 
real-time PCR (not shown). The expression of CD73 protein was confirmed by means of 
flow cytometry, as shown in Figure 35A and B. The effect of nimesulide (100 μM) on 
nitrite production was then assessed in siRNA CD73-treated cells. LPS significantly 
induced nitrite production in siRNA-treated cells (10,0 ± 4,3 μM, n=3), effect that was not 
significantly different from that of control cells (17,08 ± 2 μM, n=3). Nimesulide (100 μM) 
significantly inhibited LPS effect in control cells, while it did not impair nitrite production 
in siRNA-treated cells (Figure 35C). 
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Figure 35. Effect of nimesulide on siRNA CD73 J774. Representative flow cytometry (dot plots and 
histograms) outlining CD73 expression is shown. A) control J774, B) silenced J774 cells (siRNA-CD73-
treated J774). C) Effect of nimesulide (100 μM) on nitrite production in CTR and siRNA CD73-J774 (siRNA) 
stimulated with LPS (1 μg/ml). **p<0.01 vs. CTR/vehicle, §§ p<0.01 vs. CTR/ nimesulide. Bonferroni's 
Multiple Comparison Test  (n = 3). 
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2.3 ADENOSINE/A2A  SIGNALLING PATHWAY AND FGF-2 
2.3.1 MATERIALS AND METHODS 
2.3.1.1  Reagents  
DMSO and λ-carrageenan, were purchased from Sigma-Aldrich (Milan, Italy); CGS 21680, 
ZM 241385, were obtained from TOCRIS Bioscience (Bristol, UK); DTT, PMSF and 
leupeptin were purchased from ICN Pharmaceuticals (Italy). Polyclonal antibody to A2A 
receptor and polyclonal antibody to FGF-2 were purchased from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA). Anti-goat IgG conjugated to horseradish peroxidase was purchased 
from Dako (Denmark); anti-rabbit IgG conjugated to horseradish peroxidase was purchased 
from Jackson ImmunoResearch (West Grove, PA). Fluorescein isothiocyanate-conjugated 
anti-rabbit and biotin-conjugated anti-goat were obtained from Jackson ImmunoResearch 
(West Grove, PA). DAPI and streptavidin-Texas Red were purchased from Vector 
Laboratories (Burlingame, Ontario, Canada). Paraffin, Hematoxylin of Mayer solution and 
eosin 0.5% alcoholic solution were obtained from Kaltek (Padova, Italy). All other salts and 
reagents were purchased from Carlo Erba (Milan, Italy). 
2.3.1.2  Animals 
Male Wistar rats, body weight 200–250 g, were purchased from Harlan Nossan, (Milan, 
Italy). Animals were kept under standard conditions with food and water ad libitum and 
maintained in a 12 h/12 h light/dark cycle at 22 ± 1° C. Before the experiments, rats were 
housed and acclimatized under these conditions for four days. All the in vivo procedures 
were performed according to the Italian and European regulations (DL/2014) on the 
protection of animals used for experimental and other scientific purposes and were approved 
by Italian Ministry of Health.  
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2.3.1.3  Carrageenan-induced paw oedema 
Rats, slightly anaesthetized with 4% enflurane mixed with 0.5 L/min O2, 0.5 L/min N2O, 
received in the left hind paw 100 μL of λ-carrageenan suspension (1% w/v). Paw volume 
was measured at the time zero and each hour for 6 h by a hydropletismometer (Ugo Basile, 
Comerio, VA, Italy).  
2.3.1.4 Drug treatments 
Animals were divided in groups of 5 each and treated, just before carrageenan injection, 
with the A2A agonist,  CGS 21680 (2 mg /kg i.p.); with the A2A antagonist,  ZM 241385 (3 
mg/kg i.p.); with CGS 21680 (2 mg/kg i.p.) plus ZM 241385 (3 mg /kg i.p.) or with an equal 
volume of vehicle (DMSO). From different groups of animals, 3 hours following oedema 
induction, paws were excised, cut, frozen in liquid nitrogen or  fixed in 10 % (v/v) buffered 
formalin and stored for further analysis. Controlateral, non-injected paws (sham), were also 
excised as control tissues. 
2.3.1.5 Western blotting analysis  
Tissue samples were defrosted, weighed and homogenized with a Polytron. In order to 
extract proteins, 1 ml of  buffer (β-glycerophosphate 50 mM; sodium orthovanadate 100 
µM; MgCl2 2mM; ethylene glycol tetraacetic acid (EGTA) 1mM; DTT 1 mM; PMSF 1mM; 
Aprotinin 10µg/ml; leupeptin 10µg/ml) was added to 100 mg of tissue samples. The 
homogenates were centrifuged at 2500 rpm for 10 minutes at 4°C. The supernatants were 
then centrifuged  at 12000 rpm for 30 minutes at 4°C. Protein concentration was determined 
by the Bio-Rad protein assay kit (Bio-Rad, Italy). Denaturated samples (50 𝜇g) were 
subjected to electrophoresis on  SDS 12% polyacrylamide gel and transferred onto a 
nitrocellulose transfer membrane (Protran, Schleicher & Schuell, Germany). The 
membranes were blocked by incubation with non-fat dry milk (5% w/v) in PBS 
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supplemented with 0.1% (v/v) Tween 20  for 1 h at room temperature and then incubated 
with a rabbit polyclonal anti-FGF-2 antibody (1:1000 dilution) overnight at 4∘ C on a 
shaker. Successively, membranes were washed and then incubated with the secondary 
antibody conjugated with horseradish peroxidase, anti-rabbit IgG-HRP (1:5000 dilution) for 
2 h at room temperature. Protein bands were detected using the ECL detection kit and Image 
Quant 400 GE Healthcare software (GE Healthcare, Italy). Protein bands were quantified 
using Quantity One® software (Biorad, Italy). Successively, to confirm the equal protein 
loading, membranes were stripped and incubated with anti β-actin monoclonal antibody 
(1:2000 dilution) and subsequently with anti-mouse IgG conjugated to peroxidase (1:2000 
dilution), both for 3 h at room temperature.  
2.3.1.6 Morphological analysis  
Tissue sample  removed as described above were fixed in 10 % (v/v) buffered formalin for 
48 h and embedded in paraffin by conventional techniques. For morphological analysis, 
sections 7 µm thick, were stained with haematoxylin and eosin to demarcate cell type. The 
sections were analyzed by using a standard light microscope (x 20 objective) and 
photographed under low power. Images were taken by a Leica DFC320 video camera 
(Leica, Milan, Italy) connected to a Leica DM RB microscope using the Leica Application 
Suite software V 4.1.0.  
2.3.1.7 Picro Sirius red staining  
Picro Sirius red staining and polarization microscopy represent a powerful method for 
detecting total collagen tissue content (Junqueira et al., 1978). Briefly, the paraffin sections 
were de-waxed and rehydrate. The sections were stained with Mayer’s haematoxylin to 
visualize the nuclei and then incubated with 0.1% (w/v) Sirius red in saturated picric acid 
solution for one hour at room temperature. After washing with acidified water, slides were 
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alcohol dehydrated, mounted in a resinous medium, and visualized on a Leica Microscope 
under 90-degree polarized light.  
2.3.1.8 Immunofluorescence 
Samples were processed according to standard protocols and a series of sections of the flesh 
of paw were embedded in paraffin and cut into 7-μm-thick slices. Then, sections were 
cleared in xylene and hydrated before staining. The sections were incubated with rabbit 
polyclonal anti-FGF-2 (1:100 dilution) antibody in casein plus Triton X-100 0.3% over 
night at 4°C and then washed with PBS plus Tween 0.05% before incubation with goat 
polyclonal anti-A2A receptor (1:100 dilution) antibody in casein for 3 hours at room 
temperature. To detect co-localization of FGF-2 and A2A receptor, slides were incubated for 
30 min at room temperature with mixture of two secondary antibodies in the dark: 
fluorescein isothiocyanate-conjugated anti-rabbit antibody (1:250 dilution), and biotin-
conjugated anti-goat (1:250 dilution) antibody coupled with streptavidin-Texas Red (1:200 
dilution). Slides were then washed in PBS-Tween 0.05% and mounted in Vectashield 
Mounting Medium with DAPI (1.5 mg/mL). Images were observed using a fluorescence 
microscope Leica DM RB (Leica Microsystems, Wetzlar, Germany) equipped with 
appropriate standard filter, acquired using Leica Application Suite  V 4.1.0  software and 
then analysed using  ImageJ software (U.S. National Institutes of Health, Bethesda, MD, 
USA).  
2.3.1.9 Statistical analysis 
All results were expressed as mean ± standard error (S.E.) and analyzed by one way 
ANOVA followed by Bonferroni’s test for multiple comparisons or Dunnett’s test. A value 
of p < 0.05 was taken as statically significant. 
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2.3.2 RESULTS 
2.3.2.1 Carrageenan–induced rat paw oedema 
Injection of carrageenan into the rat hind paw caused an oedema peaking between 3 and 4 
hours. Treatment with CGS 21680 inhibited, in a dose–related manner, oedema 
development and this effect was reversed by co-administration with the A2A antagonist, ZM 
241385. On the contrary, ZM 241385 alone did not modify oedema (Figure 36).  
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Figure 36.  Effect of  CGS 21680 treatment on carrageenan–induced oedema. * p<0.05 and  **p<0.01 vs 
control. Bonferroni ‘s Multiple Comparison Test (n=10) 
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2.3.2.2 Morphological analysis 
Morphological examination of tissue sections showed cell infiltrate in inflamed tissue, 
characterized by neutrophils and degranulated mast cells (Figure 37B) that was greatly 
reduced by rat treatment with CGS 21680 (Figure 37C).                        
                                      
                                        
                                       
Figure  37. Morphological analysis . Hematoxylin and Eosin (H&E) stained paw tissue from A) sham rats, 
B) vehicle and C) CGS 21680  treated rats (n=10). Original magnification: x20. 
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2.3.2.3 Picro Sirius red staining 
Picro Sirius red staining for collagen quantification showed that in tissue section from 
inflamed animals dermal collagen appeared loose compared to paws from non-inflamed and 
from CGS 21680 treated animals where dermal elastic fibres were well organized (Figure 38 
A). Furthermore, when sections were analyzed under polarized light an increased number of 
yellow/orange collagen fibers were evident in tissue from CGS 21680 treated animals, 
compared to control tissues were greenish thinner fibers were predominant (Figure 38 B).  
 
 
 
 
 
 
 
 
 
Figure 38. Sections of paw tissue stained with Picrosirius red (A) and polarizing microscopy (B) for the 
detection of collagen. (n = 5). Original magnification: x10. 
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2.3.2.4 Western blotting analysis 
FGF-2 expression (18 kDa) in paws of CGS 21680 treated rats was increased at each hour 
following carrageenan injection (Figure 39 B) compared to the FGF-2 expression from 
inflamed and control paws (Figure 39A).  
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2.3.2.5 Immunofluorescence  
On tissue obtained as described above, A2A receptor and FGF-2 (18 kDa) were localized by 
immunofluorescence analysis (Figure 40). In control paws immunolocalization of A2AAR 
was increased compared to the immunolocalization observed in paws from CSG 21680 
treated rats suggesting that A2AAR was mostly associated with recruited inflammatory cells. 
Conversely, immunolocalization of FGF-2 was increased in paws from CGS 21680 treated 
rats compared to immunolocalization obtained in paws from control rats. 
Furthermore, spots of co-localization between A2AAR and FGF-2 were also evidenced 
(arrows).  
  
C 
Figure 39. Detection of FGF-2 by western blotting analysis in inflamed paws from vehicle (A) and CGS 
21680 (B) treated rats each hour following carrageenan injection and C) densitometric analysis (O.D. 
optical density). (n=2) 
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Figure 40. Immunofluorescence detection of A2A receptor and FGF-2 (18 kDa) on rat paws from A) 
sham, B) vehicle, C) CGS 21680 treated rats 3 h following oedema induction. n=5. 
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3. DISCUSSION  
 
3.1 CD73 AND ACUTE INFLAMMATION 
Adenosine has been recognized to be a nucleoside with autocrine/paracrine functions, acting 
as a signal molecule to preserve host defence and tissue integrity during inflammation and 
trauma. The ecto-5’nucleotidase/CD73, working in concert with the nucleoside triphosphate 
phosphohydrolases (NTPDase1/CD39), degrades AMP to adenosine and represents a key 
enzyme for adenosine accumulation at the site of injury (Antonioli et al., 2013). Its function 
would be to regulate the accumulation of adenosine into the extracellular milieu that, in 
turn, would limit tissue damage through A2A receptor activation (Palmer and Trevethick, 
2008). There is evidence that CD73 on endothelial cells plays an important role in the 
control of vascular leakage and neutrophil adhesion and migration, and its endothelial 
expression is increased under hypoxia and correlates to extracellular adenosine 
accumulation (Thompson et al., 2004). A study performed on knockout mice for CD39 and 
CD73 has shown that these enzymes represent an innate protective pathway from airway 
damage caused by mechanical ventilation, protecting from increased vascular leakage and 
cell accumulation into the lung (Eckle et al., 2007). Therefore, it has been suggested that  
CD39 and CD73 contribute to an endogenous anti-inflammatory mechanism. The 
pharmacological manipulation of endogenous mediators, actively involved in the 
downregulation of inflammation, might be an innovative anti-inflammatory strategy. Hence, 
a better understanding of the role of these enzymes in the development of inflammatory 
responses allow identifying novel molecular targets useful for developing innovative anti-
inflammatory agents. The objective of our study was to elucidate the role of CD73 in the 
development of inflammation, for this purpose we performed experiment on carrageenan-
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induced pleurisy model in rats. Carrageenan-induced pleurisy is a well-known model of 
inflammation characterized by cellular influx, fluid extravasation, and various biochemical 
parameters involved in the inflammatory response. The carrageenan pleurisy model has 
been accepted as a reliable method to study acute (4 h) and sub-acute (48-72 h) 
inflammation, providing information on cells and type of inflammatory mediators involved 
in the inflammatory process. In our experiments, through pharmacological blockade of 
CD73 by using  the selective inhibitor, APCP, the development of pleural inflammation was 
assessed 4 and 72 h after the injection of carrageenan. We found that CD73 inhibition 
significantly increased cell accumulation and exudate formation into the pleural cavity 4 h 
following carrageenan injection but did not have effect on the sub-acute phase of 
inflammation. There is evidence that the pro-inflammatory cytokines such as TNF-α,IL-1, 
IL-6, MCP-1 help to sustain the extension of a local or systemic inflammatory process.  We 
observed that CD73 inhibition increased pro-inflammatory cytokine content into the pleural 
cavity in the acute phase of inflammation while only MCP-1 levels were still significantly 
high 72 h following carrageenan injection thus confirming previous data (Reutershan et al., 
2009) that indicate the important role of CD73 in leukocyte migration. To investigate 
whether the effect of local in vivo treatment with CD73 inhibitor was due to a specific 
chemoattractant ability of APCP or was only secondary to the increase in chemotactic 
cytokine content that it caused, we also performed ex vivo experiments, on cells collected 
from the inflamed site. Interestingly we found that cells collected from APCP treated rats, 4 
hours following carrageenan-induced pleurisy showed increased ability to migrate either 
spontaneously or under a chemotactic stimulus. This finding suggests that the in vivo 
treatment with APCP not only increases the infiltration of the lung with PMNs, but may 
induce cells (PMNs) to change in a phenotype with increased ability to migrate. In parallel, 
these cells showed a reduced CD73 expression and activity compared to cells collected from 
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control group. In contrast, cells from control groups did not migrate in absence of a 
chemotactic stimulus but their ability to migrate was strongly increased following in vitro 
treatment with APCP.  Taken together, our results show that CD73 plays a major role in the 
early phase of acute inflammation, especially by controlling cell migration. The mechanisms 
underlying these effects are still to be clarified; they might be due to CD73 enzymatic 
activity and consequently, to increased extracellular adenosine and/or be independent of 
adenosine and due to a moonlighting function of CD73. Indeed although biological actions 
of e-5’NT/CD73 are mainly a consequence its enzymatic phosphohydrolytic activity,  CD73 
has also been implicated in non-enzymatic functions such as T-cell activation and cell–cell 
adhesion (Airas et al., 1995, Airas and Jalkanen, 1996; Airas, 1998; Loertscher  and Lovery, 
2002; Andrade et al., 2011). Our data, support the view that CD73/adenosine signalling 
plays an important role as endogenous modulator of inflammation and further highlight the 
importance of adenosine signalling pathway as a therapeutic target that could be 
successfully used to treat inflammatory diseases.  
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3.2 CD73/ADENOSINE/A2A SIGNALLING PATWHAY AND 
NIMESULIDE ANTI-INFLAMMATORY EFFECT 
Accumulated evidence shows that CD39 and CD73 regulate diverse physiological processes 
that are modulated by adenosine, including inflammation and that adenosine mediates its 
anti-inflammatory activity primarily through the A2AR (Fredholm et al., 1996; Antonioli et 
al., 2013). Interestingly, anti-inflammatory drugs that are widely used in clinical practice, 
such as salicylates and methotrexate, act by enhancing adenosine signalling pathway, at 
least in part, for their pharmacological activity (Cronstein et al., 1994; Montesinos et al., 
2007). This increase in adenosine is dependent on CD73 activity.   
Nimesulide (N-(4-Nitro-2-phenoxyphenyl)-methanesulfonamide) is a selective COX-2 
inhibitor that exerts anti-inflammatory activity thanks to unique chemical and 
pharmacokinetic characteristics, and to a multifactorial mechanism of action. 
Indeed, there is evidence that multiple actions of nimesulide on the inflammatory process, 
such as inhibition of PMNs activity, inhibition of histamine release from mast cells, 
inhibition of ROS production, are the consequence of regulation of the production and 
actions of a wide range of inflammatory mediators independently from the sole action on 
COX-2 activity (Rainsford, 2006).  
Various mechanisms have been proposed to explain its particular effects, among wich are  a  
direct interaction with adenosine receptors (Capecchi et al., 1993) and the inhibition of the 
enzyme phosphodiesterase IV (Bevilacqua et al., 1994).  
More recently, nimesulide has been demonstrated to improve the antirheumatic profile of 
methotrexate in a murine model of collagen–induced arthritis, with a mechanism that might 
involve adenosine (Al-Abd et al., 2010). 
Here we evaluated whether CD73/adenosine signalling was involved in the anti-
inflammatory effect of nimesulide, in vivo and in vitro.  
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We have first evaluated the effect of adenosine A2A receptor agonist, CGS 21680,  in our in 
vivo model of acute inflammation, carrageenan-induced rat paw oedema. It is a well 
characterised model of inflammation (Moore and Trottier, 1974), useful in vivo to analyse 
the mode of action of anti-inflammatory drugs and also sensitive to COX inhibitors since 
PGEs are involved (Winter et al., 1962).  
In our study CGS 21680 inhibited inflammation, as previously demonstrated in other animal 
models of inflammation  (Fozard et al., 2002; Antonioli et al., 2006; Mantell et al., 2008; 
Chen et al., 2009; Tang et al., 2010; Vincenzi et al., 2013), and its effect was clearly 
dependent upon receptor activation, since it was reversed by co-administration with the A2A 
antagonist, ZM 241385. 
Similarly, we found that nimesulide inhibited oedema development and this effect was 
partially reversed by co-treatment with ZM 241385. This result was thus suggestive of an 
involvement of adenosine A2A receptor in nimesulide anti-inflammatory effect in vivo. 
Nimesulide is a COX-2 selective inhibitor; here, we found that its anti-inflammatory effect 
was paralleled by a reduction of PGE2 plasma levels, evaluated 4 h following oedema 
induction, demonstrating that COX-2 was inhibited at the dose used. Conversely, PGE2 
plasma levels were not significantly affected by treatment with CGS 21680. This finding 
indicates that, under our experimental conditions, the anti-inflammatory pathway mediated 
by adenosine A2A receptor activation is independent of PGE2 levels, as also demonstrated in 
vitro, on mouse macrophages (Ezeamuzie and Khan, 2007). Nonetheless, the mechanism 
linking PGE2 to adenosine in the control of inflammation remains still poor understood and 
needs to be investigated more in depth. Since formation of extracellular adenosine by CD73 
is crucial to downregulate inflammatory responses either in vitro and vivo (Haskò et al., 
2011; Zimmermann et al., 2012; Antonioli et al., 2013; Chrobak et al., 2015) and  CD73 has 
also been shown to be involved in the molecular mechanism of several well-known anti-
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inflammatory drugs, we evaluated the effect of nimesulide on CD73 expression and activity 
in rat paws. 
Western blotting analysis performed on inflamed paws obtained each hour following 
oedema induction, showed that CD73 was expressed in inflamed tissue  and  there was no 
difference in paws obtained from control and nimesulide-treated rats whereas AMP 
hydrolysis in paws obtained from nimesulide-treated rats was significantly increased. This 
reflects a functional role of the e-5’NT/CD73 since local treatment with the CD73 inhibitor, 
APCP, significantly reverted the anti-inflammatory effect of nimesulide, without modifying 
the oedema development in control animals. These findings indicate that the increased 
CD73 activity, most likely via the formation of adenosine, contributes to the anti-
inflammatory effect of nimesulide in the inflamed tissue. Membrane-bound 5’-nucleotidase 
can also be shedded into the plasma and can act in concert with a soluble form of 
NTPDase1/CD39 in the hydrolysis of extracellular ATP to adenosine (Zimmermann et al., 
2012). Interestingly, we found that systemic administration of nimesulide also significantly 
increased plasma AMPase activity over basal controls. 
On the basis of our in vivo findings, we sought to better investigate the involvement of 
adenosine signalling in mediating the anti-inflammatory effect of nimesulide by performing 
in vitro experiments, on J774A.1 macrophage cell line that represents an in vitro model 
widely used to evaluate inflammatory activation/inhibition and one endpoint to evaluate the 
extent of this cell line activation is to measure nitrite production following incubation with 
LPS (D’Acquisto et al., 1997; Prestes-Carneiro et al., 2007; Shand et al.,  2011). The anti-
inflammatory role of the adenosine A2A receptor was confirmed in the J774 macrophage cell 
line in that the A2A agonist, CGS 21684, reduced nitrite production following cell activation 
with LPS and this effect was reversed by the A2A antagonist ZM 241385. Nimesulide 
inhibited nitrite production from LPS–activated J774 cells and this effect again was reverted 
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by ZM 241385. Interestingly, the effect of ZM 241385 was lost when added concomitantly 
to nimesulide (data not shown) but was only evident when it was added 6 hours thereafter, 
suggesting that adenosine A2A receptor was likely involved but not directly activated by 
nimesulide. Thus, in the light of these findings, and of results obtained in vivo, in the model 
of carrageenan–induced oedema, we investigated the effect of nimesulide on CD73 activity 
on J774 cell line. We observed that CD73 activity was reduced following J774 activation 
with LPS, which is similar to findings in LPS-activated murine peritoneal macrophages 
(Zanin et al., 2012).  Similarly, LPS was reported to downregulate CD73 activity in cultured 
cortical astrocytes (Brisevac et al., 2012). We found that pre-treatment with nimesulide 
strongly increased CD73 activity in naïve J774 cells and this effect was still evident 24 
hours following LPS-induced cell activation. Enhanced CD73 activity in the presence of 
nimesulide was confirmed in independent experiments using ε-AMP as substrate. The 
increased CD73 activity induced by nimesulide on J774 cell line reflected a functional role 
as demonstrated by evidence that specific inhibition of CD73 with APCP reverted the 
nimesulide-induced anti-inflammatory effect as evidenced by the inhibition of nitrite 
accumulation. Consistent with an increased CD73 activity, following incubation with 
nimesulide we observed a slight, not significant, reduction  in AMP production and a 
significant increase in adenosine production by both non-stimulated and LPS-stimulated 
cells. To check if nimesulide could modify CD73 expression on J774 we performed 
fluorescence-activated cell sorting (FACS) analysis but we observed that nimesulide did not 
modify CD73 surface expression in both LPS-stimulated and unstimulated J774. While the 
inhibitory effect of CGS 21680 on nitrite production by LPS-activated J774 was not 
accompanied by changes in PGE2 release, cell incubation with nimesulide led to the 
inhibition of both nitrite and PGE2 accumulation in the culture medium; both effects were 
reverted by cell treatment with ZM 241385 or with APCP. Nimesulide did not alter COX-2 
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expression on LPS-stimulated J774 evaluated by Western blotting analysis. Thus, these 
findings would correlate the in vitro anti-inflammatory effect of nimesulide to COX-2 
inhibition; on the other hand, we found that exogenously added PGE2 inhibited, in a 
concentration-related manner, nitrite production from LPS–activated J774 cells without 
affecting nitrite production from non-stimulated cells, in agreement with early studies 
(Sautebin et al., 1996; D’Acquisto et al., 1998). These results clearly suggest an important 
role of the CD73/adenosine/A2A axis to regulate macrophage function and, consequently on 
the innate immune response, as was already suggested (Alam et al., 2014;2015). It is 
therefore very likely that nimesulide by activating the CD73/adenosine/A2A pathway can 
inhibit macrophages shifting toward a pro-inflammatory phenotype following activation 
with LPS. This conclusion is in line with the observation that nimesulide was unable to 
impair nitrite production when CD73 in J774 cells was downregulated by siRNA. In order 
to evaluate whether our findings were peculiar of nimesulide or shared with other COX-2 
inhibitors, we also performed experiments on J774 macrophage cell line pre-incubated with 
another selective COX2 inhibitor, celecoxib. The effect of celecoxib at a concentration that 
inhibited PGE2 production and reduced nitrite accumulation from LPS–activated J774 was 
neither modified by ZM 241385 nor by APCP. Furthermore, consistent with an independent 
effect of nimesulide on adenosine signalling, celecoxib did not alter CD73 activity in the 
J774 macrophage cell line. Thus, in addition to the COX-2/PGE2 pathways, only nimesulide 
activates the CD73/adenosine/A2A axis. The molecular mechanisms by which nimesulide 
influences adenosine signalling is presently unclear but might involve a direct or indirect 
effect on CD73 activation. It is also possible that nimesulide may change CD73 activity by 
altering membrane fluidity (Horan et al., 1994; Sousa et al., 2008). In summary, the in-vivo 
experiments (carrageenan–induced paw oedema) and in vitro studies (J744 macrophage cell 
line) have shown that the anti-inflammatory effect of nimesulide involves the 
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CD73/adenosine/A2A signalling pathway. These results are in support of a previous 
hypothesis suggesting that nimesulide may share a common mechanism with methotrexate 
also involving adenosine acting on immune cells (Al-Abd et al., 2010). In conclusion, our 
findings contribute to delineate the biochemical mechanism underlying the pharmacological 
effect of nimesulide and  the dual mode of anti-inflammatory activity of nimesulide 
demonstrated in the present study might be exploited in the future by synthesizing COX-2 
inhibitors which in addition display a more potent activity on adenosine signalling.  
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3.3 ADENOSINE/A2A SIGNALLING PATHWAY AND FGF-2  
There is broad evidence that endogenous adenosine, generated through the action of two 
ectoenzymes, CD39 and CD73, exerts anti-inflammatory effects mainly by activation of the 
A2A receptor subtype localized on several cell types (Sitkovsky, 2003). However, the 
mechanism of A2A protective effect in inflammation needs still to be clarified. A2A 
adenosine receptor has also been shown to play a role in matrix deposition and wound 
healing in a damaged tissue, contributing to either in repairing processes or fibrotic 
disorders (Montesinos et al., 1997; Chan et al., 2006). Matrix actively participates to 
inflammatory process and can act as a reservoir for an increasing number of growth factors 
including FGF-2 (Burgess, 2009). Given evidence that A2A receptor is involved either in the 
anti-inflammatory effect and in wound healing and repairing processes mediated by 
adenosine, and given the importance of extracellular matrix and fibroblasts in either 
inflammation and repairing processes, we evaluated the effect of a well-known A2AAR 
agonist, CGS 21680, on acute inflammation development and change in extracellular matrix 
in a model of carrageenan–induced rat paw oedema. As already asserted, carrageenan–
induced rat paw oedema is a classical model of acute inflammation, widely used to  identify 
new therapeutic targets and to test the anti-inflammatory potential of new molecules. In its 
development, the intervention of great arrays of inflammatory mediators has been 
demonstrated (Vinegar et al., 1969; Di Rosa and Willoughby, 1971; Di Rosa et al., 1971). 
Local changes of epidermis and derma following injection of carrageenan have also been 
described (Vinegar et al., 1971). Firstly, to investigate the functional role of A2A in the 
control of inflammation, we treated animals with the A2A agonist, CGS 21680, or with the 
A2A antagonist, ZM 241385. We found that systemic treatment with A2A agonist, CGS 
21680, prevented oedema development and inflammation, while the A2A antagonist, ZM 
241385, did not have any effect. Furthermore, CGS 21680 inhibitory effect was prevented 
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by co-administration with ZM 241385. This finding confirms that the effect of CGS 21680 
was specific, through A2A adenosine receptor stimulation; nonetheless, A2AAR activation by 
endogenous adenosine seems not offer protection against acute inflammation since A2AAR 
antagonism did not exacerbate oedema. Moreover, this finding might suggest that CGS 
21680 would act through an indirect mechanism, involving stimulation of A2A receptor 
probably distant from the site of injury and activating anti-inflammatory mechanisms. A 
similar result was observed by Peirce et al., (2001), who demonstrated that systemic 
administration of ALT-146e, a selective A2A agonist, reduced skin ulceration induced by 
recurrent ischemia reperfusion in rats, the effect was reversed by the antagonism ZM 
241385; however, the antagonist alone did not exacerbate skin ulceration. 
In our experiments, histological analysis of tissue sections showed cells infiltration in 
inflamed tissue, characterized by neutrophils and degranulated mast cells, which was 
significantly reduced in tissue from CGS 21680 treated rats. In addition, tissue sections from 
CGS 21680 treated rats  presented much more packed tissue, without oedema.  
Morphological analysis was confirmed by performing picro Sirius red staining; indeed, the 
anti-inflammatory effect of CGS 21680 was paralleled by an increased matrix density, 
compared to tissue from control animals; furthermore, when sections were analyzed under 
polarized light an increased number of the larger yellow/orange collagen fibers 
(collagen type I) was evident in tissue from CGS 21680 treated animals, compared to 
control tissues were greenish thinner (collagen type III fibers) were predominant. So, we 
showed that CGS 21680 anti-inflammatory effect was paralleled by an increased collagen 
deposition and fibroblast proliferation, suggesting that the anti-inflammatory effect 
mediated by A2A adenosine receptor stimulation was likely due to the acceleration of matrix 
deposition. It is well known that fibroblasts contribute to the resolution of inflammation 
(Serhan et al., 2007), they can determine the nature and the duration of leukocyte infiltration 
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(Buckley et al., 2001). FGF-2 is a molecule with autocrine, paracrine and intracrine 
functions; it is a powerful mitogen for fibroblasts. Produced by several cell types and  
released by shedding vesicles or following cell damage (Taverna et al., 2003), FGF-2 plays 
a role in angiogenesis (Seghezzi et al., 1998); wound healing (Ortega et al., 1998); gastric 
ulcer protection (Pohole et al., 1999), cell proliferation (Raballo et al., 2000; Ahn et al., 
2009) and inflammation (Hu and Wu, 2001). However, although levels of FGF-2 are 
increased in inflamed tissues, its role in inflammation is still unclear. An in vitro study has 
shown that A2A activation stimulates FGF-2 production in human retinal endothelial cells 
(Valls et al., 2009). Our hypothesis was that the same mechanism(s) activated to promote 
wound healing might have been involved in the anti-inflammatory effect of A2AAR 
activation. This hypothesis was also supported by evidence that, as already mentioned, 
extracellular matrix is actively involved in resolution of inflammation, A2A stimulation 
accelerate matrix deposition and that FGF-2, largely involved in wound healing, also shows 
anti-inflammatory effects (Hu and Wu, 2001; Jeon et al., 2007). In our experiments, 
changes in extracellular matrix morphology, following rat treatment with A2A agonist, were 
evident by tissue staining with Picrosirius red. Western blotting analysis of inflamed  tissues 
showed increased FGF-2 expression following rat treatment with CGS 21680 compared 
either to control or to not inflamed paws. To better analyze tissue from control and CGS 
21680 treated rats and to further evaluate whether changes observed were peculiar of the rat 
treatment with the A2A agonist, rather than reflecting a no inflamed paw, we performed 
immunofluorescent analysis of tissues to localize A2A receptor and FGF-2, 3 h following 
oedema induction that represented the inflammatory peaking point. Interestingly, we found 
that A2A receptor was highly localized in derma of inflamed paws (control paws) while 
scarcely present in the other two groups suggesting that the increased A2A expression in 
inflamed tissues is mainly representative of receptor expressed by infiltrating cells. 
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Conversely, FGF-2 was largely localized in derma of tissues obtained from CGS 21680 
treated animals; interestingly, there were spots of co-localization between FGF-2 and A2A , 
leading us to hypothesise about a relationship between  adenosine/A2AAR and FGF-2. Our 
hypothesis would be consistent with the finding of a direct physical interaction between 
A2AAR and FGF-2 receptor system already reported (Flajolet et al., 2008). 
In conclusion, in our study, by using an in vivo model of inflammation, we have 
demonstrated  that the anti-inflammatory effect of A2AAR activation is paralleled by an 
increased expression of FGF-2 that, in turn, might participate in matrix deposition. 
Therefore, A2AAR agonists might be valuable anti-inflammatory agents able to target cells 
as fibroblasts and provide a new range of possibilities in the anti-inflammatory therapy. 
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4. CONCLUSIONS 
 
Adenosine is a key regulatory molecule, mostly protective but in certain scenarios injurious, 
in the pathophysiology of inflammatory diseases (Haskó  and Pacher, 2008). Activation of 
adenosine receptors might be advantageous in the treatment of various inflammatory 
disorders such as rheumatoid arthritis, psoriasis, sepsis (Chen et al., 2013); therefore, 
adenosine receptors represent a promising drug target. At present, due to its widespread and 
pleiotropic effects and to a short half-life, the clinical uses of adenosine are limited to 
termination of supraventricular tachycardia (Krenosin®, Adenocard®; 6 mg/2 ml, for iv. 
use)  or in conjunction with thallous (thallium) chloride TI 201 for myocardial perfusion 
scintigraphy (thallium stress test) in patients unable to undergo adequate stress testing with 
exercise (Adenoscan® ; adenosine 30 mg/10 ml, for iv. use). For each of the four ARs 
subtypes, selective agonists and antagonists and positive allosteric modulators have been 
developed by introducing several modifications in the structure of the lead compounds 
(adenosine and methylxanthine). CGS 21680 is a well-known, specific A2A agonist. 
Experiments performed and shown in the present Ph.D. thesis have demonstrated a cross-
talk between adenosine/A2A signalling and FGF-2 that may supply a new range of 
possibilities in the anti-inflammatory therapies. In particular, inflammatory skin diseases, 
that have a significant impact on the quality of life of patients, could take advantage by A2A 
receptor agonists since A2A receptor activation shows to inhibit the inflammatory and to 
promote tissue repair. In agreement with this view, it has been proved that topical 
application of CGS 21680 effectively protects against phorbol-induced epidermal 
hyperplasia and inflammation in mice, without the deleterious atrophic effect of topical 
corticosteroids (Arasa et al., 2014).  
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The development of A2AAR agonists as therapeutic agents in inflammatory disorders is 
limited by evidence that A2A activation reduces blood pressure  (Nekooeian and Tabrizchi, 
1996). Therefore, it is necessary to develop  A2A agonists able to exert their effect with a 
tissue selectivity.  
Up to now, the only A2A agonists in clinical studies are administered as inhalation 
formulations in patients with asthma or COPD (Antonioli et al., 2014).  
Besides A2A agonists, other drugs targeting adenosine receptors are in clinical trials; for 
instance, based on preclinical pharmacology and encouraging safety data in Phase I studies, 
the A3 receptor agonists CF101 and CF102 have been tested in several Phase II trials for 
rheumatoid arthritis (Silverman et al., 2008). Based on anecdotal findings from this trial 
indicating that CF101 also improves indicators of dry eye syndrome, a follow-up Phase II 
trial (randomized, double-blind and placebo-controlled) has been carried out, which has 
determined that CF101 improves the clearance of corneal staining, tear break-up time and 
tear meniscus height (Avni et al., 2010). The efficacy and safety of CF101 has been also 
tested in a Phase II trial of moderate to severe chronic plaque-type psoriasis; it has been 
found to be effective and thus advanced to Phase III trials for these indications as an anti-
inflammatory agent (Fishman et al., 2012). 
Despite a large number of selective adenosine receptor agonists and antagonists reported in 
the literature, the clinical application of adenosine ligands is very limited. Only one 
adenosine receptor-specific agent, the adenosine A2A receptor agonist regadenoson 
(Lexiscan; Astellas Pharma), has so far gained approval from the Food and Drug 
Administration (FDA); it is a coronary vasodilator that is commonly used in pharmacologic 
stress testing. There are several factors that need to be explored, for example, the function of  
systemic and local adenosine receptors, in disease models and in humans; the careful 
examination of adenosine signalling and the effects of the drug over the continuum of 
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specific disease courses (for instance, acute and chronic stages of a disease); clinical studies 
in which individual differences are carefully monitored and related to background factors, 
such as caffeine use (the daily consumption of three to four regular cups of coffee results in 
approximately 50% A1 and A2A receptor occupancy for several hours; Fredholm et al., 
1999) and the examination of the possibility of combining direct adenosine receptor actions 
with drugs targeting other pathways and/or targets (Chen et al., 2013).  
Moreover, adenosine receptors are found on many cells in the body, so that agonists of these 
receptors might have negative side effects which make them difficult to use. Another 
potential complication is the differential effects of adenosine receptor activation (or 
inactivation) at different stages in development; for instance in newborn mice, A1 receptor 
agonism appears to have a harmful effect in response to hypoxia-induced brain injury, 
whereas in adult mice it has a protective effect (Turner et al., 2003).  
A possible approach for achieving tissue selectivity could be the use of partial agonists that 
would predominantly act where there is a high number of “spare” receptors or the use of 
allosteric modulators. CF602, an A3 adenosine receptor allosteric modulators, developed by 
the biotechnology company Can-Fite BioPharma, could be useful in a variety of 
autoimmune and inflammatory disorders (Antonioli et al., 2014).  Alternatively, strategies 
that are capable of interfering with the function of enzymes and transporters that are 
responsible for the accumulation of extracellular adenosine at inflammatory sites may have 
more general applicability. For example, beneficial effects have been observed with the 
pharmacological blockade of ADA in experimental model of colitis (Antonioli et al., 2007; 
Brown et al., 2008) and sepsis (Adanin et al., 2002; Cohen et al., 2002; Kayhan et al., 2008) 
and using AK inhibitor in experimental model of arthritis, colitis and in diabetic retinopathy 
(Suzuki et al., 2001; Siegmund et al., 2001; Elsherbiny et al., 2013) or nucleoside 
transporter inhibitors in models of inflammatory pain and inflammatory lung injury (Maes 
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et al., 2012; Morote-Garcia et al., 2013). To date, the adenosine uptake inhibitor 
dipyridamole is used in patients for pharmacological stress echocardiography (as a coronary 
vasodilator) or as an inhibitor of platelet aggregation. An FDA-approved adenosine 
deaminase inhibitor, deoxycoformycin (Nipent; Astex Pharmaceuticals), can increase 
extracellular adenosine levels and is currently in clinical use for the treatment of 
haematological malignancies. At the same time, the development of adenosine-regulating 
compounds as prodrugs, based on our understanding of the ATP-dependent adenosine 
signalling cascade, that are able to increase adenosine concentration in a site and event 
specific manner, seems to be very promising (El-Tayeb et al., 2009). Flögel and co-workers 
(2012) have synthesised a phosphorylated prodrug A2AR agonist, which is specifically 
activated by CD73 overexpressed on immune cells. Once it is locally administered into the 
joint of arthritic mice, this prodrug reduces inflammation, without inducing vasodilatory 
side effects, due to profound up-regulation of CD73 and adenosine A2AR expression in 
neutrophils and inflammatory monocytes in the synovial fluid of arthritic mice. The 
modulation of CD73 enzymatic activity, in order to enhance the extracellular adenosine 
formation, may thus represent a therapeutic strategy in the treatment of inflammation. At 
present, clinical trials are being carried out to increase extracellular adenosine levels in 
humans (Chen et al., 2013). Our data obtained in carrageenan-induced pleurisy in rat 
support the view that CD73/adenosine signalling plays an important role as an endogenous 
modulator of inflammation and further highlight the importance of adenosine signalling 
pathway as a therapeutic target that could be successfully used to treat inflammatory 
diseases. CD73 directed therapies have not yet been developed. Alternatively, 
administration of soluble 5’-nucleotidase/CD73 has been shown to be advantageous in a 
number of experimental inflammatory models, especially by promoting vascular barrier 
function and by decreasing neutrophil accumulation, according to our results collected in 
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carrageenan-induced pleurisy model. With regard to this, a big limitation could be the 
identification of a reliable source of purified protein.   
As already asserted,  anti-inflammatory action of some drugs is explained by the increase of 
extracellular adenosine concentrations (Amann and Peskar, 2002; Montesinos et al., 2007). 
For instance, on the basis of the finding that the beneficial effect of  IFN- in multiple 
sclerosis has been associated to CD73 upregulation, an open-label study has been initiated, 
where IFN--induced up-regulation of human lung CD73 expression and soluble 5’-
nucleotidase activity has shown to be associated with reduced mortality in patients with 
acute respiratory distress syndrome (Bellingan et al., 2014). On this basis, a section of the 
research work described in this thesis demonstrates that the anti-inflammatory effect of the 
COX-2 inhibitor nimesulide is, in part, mediated by CD73-derived adenosine acting on A2A 
receptors. Thus, pharmacological agents able to raise the extracellular levels of endogenous 
adenosine, including nimesulide, might be exploited in the future to project drugs that might 
have an anti-inflammatory effect by targeting an endogenous anti-inflammatory pathway, 
representing, in this way, an innovative anti-inflammatory strategy. 
In conclusion, it has become increasingly clear the need for identification of novel 
molecular targets for the development of new anti-inflammatory agents. Adenosine 
signalling represents a powerful  modulator of the inflammatory response, as well confirmed 
by our findings described in this thesis. An innovative strategy can be represented by the 
pharmacological manipulation of endogenous anti-inflammatory pathways. Targeting 
multiple steps and pathways involved in adenosine signalling, such as adenosine generation 
and metabolism as well as adenosine receptors themselves, may be synergistic and more 
efficacious than targeting an individual step or pathway (Chen et al., 2013) and may 
represents a valuable strategy to project innovative anti-inflammatory drugs with a more 
favourable pharmacodynamics/pharmacokinetic and safety profile.   
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